Monoclonal antibodies targeting g protein-coupled receptor 124 (GPR124) and methods of their use

Fully human monoclonal antibodies targeting GPR124 enhance drug delivery across the BBTB, addressing the treatment challenges of brain tumors and metastases by increasing drug permeability and reducing tumor vasculature.

WO2026241272A2PCT designated stage Publication Date: 2026-11-19THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027815
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current therapies for brain tumors and brain metastases are hindered by the blood-brain-tumor barrier (BBTB), which limits the delivery of therapeutic agents, and there are no known antibody-based agents that can selectively open this barrier for effective treatment.

Method used

Development of fully human monoclonal antibodies that bind GPR124 with high affinity, enabling enhanced delivery of therapeutic agents across the BBTB and targeting GPR124-expressing tumor vasculature for cell killing, utilizing antibody formats such as scFv, Fab, and IgG, as well as fusion proteins, CARs, and ADCs.

Benefits of technology

The antibodies effectively enhance the delivery of therapeutic agents across the BBTB, improving treatment efficacy for brain tumors and metastases by increasing drug permeability and reducing tumor vasculature, as demonstrated in preclinical models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027815_19112026_PF_FP_ABST
    Figure US2026027815_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Monoclonal antibodies that bind G protein-coupled receptor 124 (GPR124), as well as conjugates thereof, are described. The anti-GPR124 monoclonal antibodies and conjugates can be used, for example, to enhance the delivery of a therapeutic agent (such as an anti-tumor agent) across the blood-brain-tumor barrier (BBTB), thereby allowing for the treatment of a disease or disorder of the central nervous system (CNS) by increasing delivery of the therapeutic agent to the CNS. The anti-GPR124 antibodies and conjugates thereof can also be used to reduce or inhibit the development of tumor vasculature.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 4239-113261-02

[0002] MONOCLONAL ANTIBODIES TARGETING G PROTEIN- COUPLED RECEPTOR 124

[0003] (GPR124) AND METHODS OF THEIR USE

[0004] CROSS REFERENCE TO RELATED APPLICATIONS

[0005] This application claims the benefit of U.S. Provisional Application No. 63 / 804,833, filed May 13, 2025, which is herein incorporated by reference in its entirety.

[0006] FIELD

[0007] This disclosure concerns monoclonal antibodies that bind G protein-coupled receptor 124 (GPR124) and their use, such as for enhancing traversal of therapeutic agents across the blood-brain-tumor barrier (BBTB) and reducing or inhibiting the development of tumor vasculature.

[0008] INCORPORATION OF ELECTRONIC SEQUENCE LISTING

[0009] The electronic sequence listing, submitted herewith as an XML file named 4239-113261-O2.xml (23,252 bytes), created on May 4, 2026, is herein incorporated by reference in its entirety.

[0010] BACKGROUND

[0011] With a median survival of 12-18 months and a five-year survival rate of only 5%, glioblastoma is a deadly brain tumor in urgent need of improved therapies. Brain metastases from breast cancer, lung cancer and melanoma are also a common complication of non-CNS cancer types with dismal survival outcomes. For instance, brain metastases (BMs) occur in 20-40% of patients with breast cancer during the course of their disease. The risk of brain metastasis is typically highest for those with aggressive types of breast cancer, including HER2 -positive breast cancer. Patients with breast cancer brain metastases (BCBMs) have a poor survival rate, with only 20% surviving after 1 year. Furthermore, the delivery of therapeutic agents to treat brain malignancies is inhibited by the presence of the so-called blood-brain tumor barrier (BBTB) which limits permeability and the amount of drug that can reach these tumors.

[0012] While the blood-brain barrier (BBB) functions to protect the central nervous system (CNS) from pathogens and regulate tire microenvironment of tire CNS, brain tumors partially compromise the integrity of tire BBB. The neovasculature of brain tumors is typically more permeable than surrounding CNS vasculature, but less permeable than the vasculature of non-CNS healthy tissue. Therefore, tumors within the brain maintain a BBTB where some heterogeneous barrier properties persist and limit penetration and diffusion of drugs within tumors, thereby posing a significant obstacle for the delivery of therapeutics to heat both primary brain tumors and brain metastases.

[0013] Currently, there are no known antibody-based agents that can selectively open the BBTB to enable effective treatment. The endothelial G-protein-coupled receptor GPR124 (also known as tumor endothelial marker 5 - TEM5) is an important regulator of neurovasculature development and4239-113261-02

[0014] BBB function via Wnt7 / p-catenin signaling. The activation of this signaling is essential for promoting barrier properties in proliferating brain tumor endothelium, while its role in maintaining the BBB of normal resting brain endothelium is non-essential.

[0015] SUMMARY

[0016] Disclosed herein are fully human monoclonal antibodies that bind human and mouse GPR124 with high affinity. The disclosed antibodies and conjugates thereof can be used, for example, to enhance the delivery of therapeutic agents across the BBTB, and to target GPR124-expressing tumor vasculature for cell killing.

[0017] Provided herein are monoclonal antibodies that bind GPR124. In some aspects, the monoclonal antibodies include a variable heavy (VH) domain having a heavy chain complementarity determining region 1 (HDR1), a HCDR2 and a HCDR3, and a variable light (VL) domain having a light chain complementarity determining region 1 (LDR1), a LCDR2 and a LCDR3. In some examples, the VH domain includes the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 1 and the VL domain includes the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 2. In other examples, the VH domain includes the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 3 and the VL domain includes the LCDR1 , LCDR2 and LCDR3 sequences of SEQ ID NO: 4. In some examples, the monoclonal antibody is an antigen-binding fragment, such as a single chain variable fragment (scFv) or a fragment antigen-binding (Fab). In other examples, the monoclonal antibody is an IgG.

[0018] Also provided are fusion proteins, multi-specific antibodies, chimeric antigen receptors (CARs), immunoconjugates, antibody-nanoparticle conjugates, antibody-drug conjugates (ADCs) and antibody-proteolysis targeting chimera (PROTAC) conjugates that include a GPR124-targeted monoclonal antibody disclosed herein. Isolated cells, such as immune cells, expressing GPR124-targeted CARs, are also provided.

[0019] Further provided are nucleic acid molecules and vectors that encode a monoclonal antibody, fusion protein, multi-specific antibody, CAR or immunoconjugate disclosed herein.

[0020] Also provided are compositions drat include a pharmaceutically acceptable carrier and a monoclonal antibody, fusion protein, multi-specific antibody, CAR, CAR-expressing cell, immunoconjugate, antibody-nanoparticle conjugate, ADC, antibody-PROTAC conjugate, nucleic acid molecule or vector disclosed herein.

[0021] Further provided are methods of treating a disease or disorder of the central nervous system (CNS) in a subject in need thereof. In some aspects, the method includes administering to the subject an effective amount of a monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate, or composition disclosed herein; and administering to the subject a therapeutic agent for the treatment of the CNS disease or disorder. The effective amount of the monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate, or composition is an4239-113261-02

[0022] amount that increases delivery of the therapeutic agent across the BBTB compared to delivery of the therapeutic agent in the absence of the monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate or composition. In the context of this method, the therapeutic agent refers to a therapeutic agent that is not the GPR124-specific monoclonal antibody, fusion protein, multi- specific antibody, antibody-PROTAC conjugate, or composition. The therapeutic agent is any agent capable of treating the disease or disorder of the CNS, the delivery of which is increased by administration of the GPR 124- targe ted monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate, or composition.

[0023] Also provided are methods of inhibiting or reducing tumor vasculature in a subject with a tumor. In some aspects, the method includes administering to the subject an effective amount of a monoclonal antibody, fusion protein, multi-specific antibody, CAR, isolated cell, immunoconjugate, antibody-nanoparticle conjugate, ADC, nucleic acid molecule, vector, antibody-PROTAC conjugate, or composition disclosed herein.

[0024] The foregoing and other features of this disclosure will become more apparent from the following detailed description of several aspects which proceeds with reference to the accompanying figures.

[0025] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1: Fully human antibodies that bind GPR124. Using a highly diverse human phage antibody display library, a panel of scFv antibodies that could bind human and mouse GPR124 were identified. Flow cytometry was used to assess binding of two of the identified antibodies (T502 and T519) and a non-specific IgG control to 293 SuperTopFlash (STF) cells 48 hours post transient transfection of GPR124 / pcDNA3 or pcDNA3 empty vector (EV). The results show that T502 and T519 bind GPR124-expressing 293 cells.

[0026] FIGS.2A-2B: Identification of GPR124 antibodies that block Wnt7 / p-catenin signaling. The anti-GPR124 antibodies T519 and T502 were tested for their ability to block Wnt7 / p-catenin signaling in HEK293-STF reporter cells. The STF cells contain a TCF / LEF-luciferase reporter that allows for monitoring of GPR124 dependent Wnt7 / -catenin signaling. HEK293-STF cells were cotransfected with WNT7A, RECK and human GPR124 (JiGPR124) constructs and heated for 48 hours with 100 itg / mL of non-specific IgG, T502 scFv or T519 scFv (FIG. 2A), or non-specific IgG, T502 IgG or T519 IgG (FIG. 2B). The results showed that both T502 and T519 blocked signaling in scFv format, but only T502 blocked signaling in IgG format.

[0027] FIGS.3A-3B: All formats of the GPR124-targeted T502 antibody block Wnt7 / p-catenin signaling. Three antibody formats of T502 (scFv, Fab and full IgG) were tested at various concentrations for function blocking activity in STF reporter cells. Shown are luciferase dose-4239-113261-02

[0028] response values of HEK293-STF cells co-transfected with WNT7A, RECK and hGPR124 (FIG. 3A) or mGprl24 (FIG. 3B) vectors and treated for 48 hours with 0 to 100 |ig / mL of control IgG or T502 antibody in scFv, Fab and full IgG format. All three antibody formats potently blocked Wnt7 / 0-catenin signaling in reporter cells. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

[0029] FIG.4: High binding affinity of the T502 antibody. The N-terminal extracellular domains (EDs) of human or mouse GPR124 were purified from mammalian cells. Each protein was coated at 1000 RU on a new CM5 chip in acetate buffer pH 5.0. The T502 and T519 anti-GPR124 antibodies in Fab (monovalent) format were purified and tested at 6.25, 12.5, 25, 50 and 100 nM, using the Single Cycle Program. Surface plasmon resonance (SPR) data were fitted with the monovalent binding model, and the rate constant was calculated accordingly. Both Fabs were found to recognize human and mouse GPR124. Fab502 (KD~ 0.35 nM) had a higher affinity than Fab519 (KD~ 69-93 nM), mainly due to its slow dissociation rate (kd).

[0030] FIGS.5A-5B: T502 IgG binds to human and mouse GPR124. Flow cytometry was used to monitor binding of T502 to 293 cells transiently transfected with mouse GPR124 (mGprl 24) or human GPR124 (hGPR124) expression vectors. Cells transfected with pcDNA empty vector were used as a negative control. Cells stained with a non-binding IgG were also included as a negative control. (FIG. 5A) No binding of control IgG was detected in cells transfected with pcDNA or vectors encoding human or mouse GPR124. (FIG. 5B) T502 binds cells expressing both human and mouse GPR124.

[0031] FIG.6: T502 binds to GPR124 but not GPR125. Flow cytometry was used to monitor binding of T502 to 293 cells transiently transfected with human or mouse GPR125 expression vectors (JiGPR124 and mGprl24, respectively). GPR125 is the closest homologue of GPR124, and unable to potentiate Wnt7 signaling. The results show that T502 binds GPR124 (left panel), but is unable to bind human or mouse GPR125 (middle and right panels).

[0032] FIG.7: T502 enhances permeability in GPR124-positive cells. Gprl24 knockout (KO) brain endothelial cells (BECs) were isolated from Gprl24 KO mice, immortalized, then transfected with a doxycycline (Dox)-inducible GPR124 expression vector. Untreated cells (GPR124 ) or cells cultured with doxycycline (GPR124+) were untreated or treated with T502 anti-GPR124 antibody. The results show that T502 was only able to block impedance (barrier properties) in cells expressing GPR124.

[0033] FIG.8: HER2 and CD276 expression in brain metastatic breast cancer models. Before testing the ability of T502 to enhance the activity of antibody-drug conjugates (ADCs), ADC target expression on the brain metastatic breast cancer lines was verified. Flow cytometry was used to monitor expression of HER2 and CD276 in three brain metastatic breast cancer cell lines using the trastuzumab (HER2) and m276-SL (CD276) antibodies. Both surface proteins are expressed in each of the cell lines. IgG-SL is a non-binding IgG control that has the same Fc domain as trastuzumab and m276-SL.4239-113261-02

[0034] FIGS. 9A-9F: T502 does not impact drug responses in tumor cell cytotoxicity assays. (FIGS.

[0035] 9A-9C) Alamar blue assays were used to monitor viability of JIMT1-BR3 cells treated with pyrrolobenzodiazepine (PBD)-labelled ADCs (FIGS. 9A-9B) or Abraxane (FIG. 9C), in the presence of 50 |ig / mL of non-binding IgG or 50 pg / mL of T502. The IC50 values for die treatments are shown below each graph. T502 had no direct impact on cancer cell viability in vitro. (FIGS. 9D-9E) Alamar blue assays were used to monitor viability of HCC1954-SBM and SUM190-BR3 cells treated with PBD-labelled ADCs. (FIG. 9F) IC50 values for the treatments shown in FIGS. 9D-9E.

[0036] FIGS. 10A-10D: CD276 and HER2 maintain high expression in brain metastases in vivo. Immunofluorescence staining was used to assess CD276 staining (FIGS. 10A-10B) or HER2 staining (FIGS. 10C-10D) in breast cancer brain metastases from HCC19540SBM (FIGS. 10A and 10C) or JIMT1-BR3 (FIGS. 10B and 10D). Tumor cells were labelled with GFP and co-localization of signal indicates that CD276 and HER2 are expressed in tumor cells.

[0037] FIG. 11: T502 detects GPR124 in tumor vessels of JIMT1-BR3 brain metastases.

[0038] Immunofluorescence staining with the T502 antibody was used to assess GPR124 expression in the vasculature of JIMT1-BR3 breast cancer brain metastases. Tumor cells were labelled with GFP.

[0039] FIG. 12: The role of GPR124 in the BBTB. To investigate the impact of GPR124 on the BBTB, Gprl24 conditional KO mice were treated with tamoxifen to genetically disrupt Gprl24 in endothelial cells. Afterwards, GL261 tumor cells were injected intracranially. Once brain tumors formed, sulfo-NHS-biotin tracer was then injected intracardially and brains harvested to assess leakage from brain vasculature.

[0040] FIGS. 13A-13B: Endothelial Gprl24 deficiency increases leakage of tracer molecule in brain tumors. (FIG. 13A) Immunofluorescence staining with Texas Red-streptavidin was used to assess the localization of sulfo-NHS-biotin in Gprl24 wildtype (WT) mice or endothelial cell (EC) Gprl24 conditional knockout (CKO) mice. The biotin tracer remained mostly inside the CD31 positive vessels in tumors from WT mice (left), but readily leaked from tumor vessels in Gprl24 EC CKO mice (right). (FIG. 13B) Quantification of the leaked (non-CD31 overlapping) sulfo-NHS-biotin.

[0041] FIGS. 14A-14C: T502 augments Trastuzumab-SL-PBD activity against JIMT1-BR3 breast cancer metastasis and extends overall survival in an animal model. (FIG. 14A) Animal study plan for treatment with die combination of anti-GPR124 and Trastuzumab-SL-PBD. (FIG. 14B) Bioluminescence imaging (BLI) was used to monitor growth of luciferase tagged IIMT1-BR3 cells following intracardiac injection. (FIG. 14C) Kaplan-Meier analysis was used to monitor survival of the mice shown in FIG. 14B.

[0042] FIGS. 15A-15C: T502 improves the activity of Abraxane against JIMT1-BR3 brain metastatic breast cancer. (FIG. 15A) Treatment schedule for in vivo study with Abraxane and T502. (FIG. 15B) BLI imaging of the mice from day 7 to 28. One representative mouse per group is shown. (FIG. 15C) Kaplan-Meier analysis was used to monitor survival.4239-113261-02

[0043] FIGS. 16A-16B: (FIG. 16A) T502 improves the activity of Trastuzumab-SL-PBD against HCC1954-SBM brain metastatic breast cancer. Kaplan-Meier analysis was used to monitor survival. (FIG. 16B) T502 improves the activity of m276-SL-PBD against HCC1954-SBM brain metastatic breast cancer. Kaplan-Meier analysis was used to monitor survival.

[0044] FIGS. 17A-17C: Markers of BBTB are reduced in E0771-BR5 brain metastases following endothelial cell deletion of GPR124. (FIG. 17A) Schematic of strategy used to create samples for immunofluorescence analysis of BBTB markers. (FIG. 17B) Immunofluorescence staining (left panel) reveals lower GLUT1 levels in the CD31 positive vessels of tumors from conditional Gprl24 knockout (EC KO) versus Gprl24 heterozygous (EC het) mice. The right panel shows quantification of tire immunofluorescence staining. GLUT1 regulates glucose transport and in this experiment its levels are being used as a marker of barrier properties. (FIG. 17C) Immunofluorescence staining (left panel) reveals lower MFSD2A levels in the CD31 positive vessels of tumors from conditional Gprl24 knockout (EC KO) versus Gprl24 heterozygous (EC het) mice. The right panel shows quantification of the immunofluorescence staining. MFSD2A regulates transcytosis and in this experiment its levels are being used as a marker of barrier properties, ns; non-significant, **p<0.01, ****p<0.0001.

[0045] FIGS. 18A-18C: Markers of BBTB are reduced in E0771-BR5 brain metastases following endothelial cell deletion of GPR124. (FIG. 18A) Immunofluorescence staining of CD31 , claudin-5, and tumor cells in non-involved normal mouse brain of conditional Gprl24 knockout (EC KO) versus Gprl24 heterozygous (EC het) mice. (FIG. 18B) Immunofluorescence staining of CD31, claudin-5, and tumor cells in a EO771-BR5 breast cancer brain metastasis from conditional Gprl24 knockout (EC KO) versus Gprl24 heterozygous (EC het) mice. (FIG. 18C) Quantification of the immunofluorescence staining of Claudin 5. Claudin 5 regulates tight junction formation and in this experiment its levels are being used as a marker of barrier properties, ns; non-significant, **p<0.01.

[0046] FIGS. 19A-19D: Increased perfusion of Sulfo-NHS-Biotin tracer in E0771-BR5 brain metastases following endothelial cell deletion of GPR124. (FIG. 19A) Schematic of the strategy used to create samples for immunofluorescence analysis of perfusion. (FIG. 19B) Quantification of the immunofluorescence staining to detect Sulfo-NHS-Biotin using fluorescently-labelled streptavidin. *p<0.05, ****p<0.0001. (FIGS. 19C-19D) Immunofluorescence staining of CD31, Sulfo-NHS-Biotin, and tumor cells in a E0771-BR5 metastasis from a Gprl24 heterozygous (EC het) mouse (FIG. 19C) versus conditional Gprl24 knockout (EC KO) (FIG. 19D).

[0047] FIGS.20A-20C: Treatment of mice bearing JIMT1-BR3 brain metastases with T502 reduces BBTB marker MFSD2A. (FIG. 20A) Schematic of the strategy used to create samples for immunofluorescence analysis of BBTB markers. (FIG. 20B) Immunofluorescence staining reveals lower MFSD2A levels in the CD31 positive vessels of tumors following treatment with T502 versus vehicle. (FIG. 20C) Quantification of the immunofluorescence staining. MFSD2A regulates transcytosis and in this experiment its levels are being used as a marker of barrier properties, ns; nonsignificant, **p<0.01.4239-113261-02

[0048] FIGS.21A-21C: Immunofluorescence staining of brain metastases reveals more antibody-fluorophore conjugate (AFC) bound to tumor cells following T502 administration. (FIG. 21A) Schematic of the strategy used to create samples for immunofluorescence analysis of BBTB markers. (FIG. 2 IB) Immunofluorescence staining reveals increased levels of B7H3 targeted AFC on GFP positive tumor cells following pretreatment with T502 antibody (versus vehicle). In this experiment, vessels are stained with CD31 and nuclei are stained with DAPI. (FIG. 21C) Quantification of the immunofluorescence staining. ****p<0.0001.

[0049] FIGS.22A-22B: T502 improves survival following m276-SL-PBD ADC treatment of mice with JIMT1-BR3 brain metastases. (FIG. 22 A) Animal study plan for treatment with the combination of anti-GPR124 and m276-SL-PBD. (FIG. 22B) Kaplan-Meier analysis was used to monitor survival of mice from the study outlined in FIG. 22A.

[0050] SEQUENCES

[0051] The amino acid sequences listed in the accompanying sequence listing are shown using single letter code for amino acids, as defined in 37 C.F.R. 1.822. In the accompanying sequence listing:

[0052] SEQ ID NO: 1 is the amino acid sequence of the VH domain of antibody T502.

[0053] SEQ ID NO: 2 is the amino acid sequence of the VL domain of antibody T502.

[0054] SEQ ID NO: 3 is the amino acid sequence of the VH domain of antibody T519.

[0055] SEQ ID NO: 4 is the amino acid sequence of the VL domain of antibody T519.

[0056] SEQ ID NOs: 5-26 are the amino acid sequences of the T502 and T519 CDRs.

[0057] DETAILED DESCRIPTION

[0058] I. Abbreviations

[0059] ADC antibody-drug conjugate

[0060] BBB blood- brain barrier

[0061] BBTB blood- brain-tumor barrier

[0062] BEC brain endothelial cell

[0063] BLI bioluminescence imaging

[0064] CDR complementar ity determining region

[0065] CKO conditional knockout

[0066] CNS central nervous system

[0067] Dox doxycycline

[0068] EC endothelial cell

[0069] ED extracellular domain

[0070] Fab fragment antigen- binding

[0071] GPR124 G protein-coupled receptor 1244239-113261-02

[0072] HCDR heavy chain complementarity determining region

[0073] IC50 half-maximal inhibitory concentration

[0074] KO knockout

[0075] LCDR light chain complementarity determining region

[0076] PBD pyrrolobenzodiazepine

[0077] PROTAC proteolysis targeting chimera

[0078] scFv single chain variable fragment

[0079] SPR surface plasmon resonance

[0080] VH variable heavy

[0081] VL variable light

[0082] II. Summary of Terms

[0083] Unless otherwise noted, technical terms are used according to conventional usage.

[0084] Definitions of many common terms in molecular biology may be found in Krebs et al. (eds.), Lewin’s genes XII, published by Jones & Bartlett Learning, 2017. As used herein, the singular forms “a,” “an,” and “the,” refer to both the singular as well as plural, unless the context clearly indicates otherwise. For example, the term “an antigen” includes singular or plural antigens and can be considered equivalent to the phrase “at least one antigen.” As used herein, the term “comprises” means “includes.” It is further to be understood that any and all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for descriptive purposes, unless otherwise indicated. Although many methods and materials similar or equivalent to those described herein can be used, particular suitable methods and materials are described herein. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. To facilitate review of the various aspects, the following explanations of terms are provided:

[0085] Administration: The introduction of a composition into a subject by a chosen route.

[0086] Administration can be local or systemic. For example, if the chosen route is intravenous, die composition is administered by introducing die composition into a vein of the subject. Exemplary routes of administration include, but are not limited to, oral, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, intratumoral, and intravenous), sublingual, rectal, transdermal (for example, topical), intranasal, vaginal, and inhalation routes.

[0087] Antibody: An immunoglobulin, antigen-binding fragment, or derivative thereof, that binds (such as specifically binds) and recognizes an analyte (antigen) such as GPR124 / TEM5. The term “antibody” is used herein hi the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies4239-113261-02

[0088] (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigenbinding activity.

[0089] Non-limiting examples of antibodies include, for example, intact immunoglobulins and variants and fragments thereof known in the art that retain binding affinity for the antigen. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab’-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv, VHH); and inulti specific antibodies formed from antibody fragments. Antibody fragments include antigen binding fragments either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA methodologies (see, e.g., Kontermann and Diibel (Eds.), Antibody Engineering, Vols. 1-2, 2nded., Springer-Verlag, 2010).

[0090] A single-chain variable fragment antibody (scFv) is a genetically engineered molecule containing the VH and VL domains of one or more antibody(ies) linked by a suitable polypeptide linker as a genetically fused single chain molecule (see, for example, Bird et al. , Science, 242(4877):423-426, 1988; Huston et al., Proc. Natl. Acad. Sci. U.S.A., 85(16):5879-5883, 1988; Ahmad etal., Clin. Dev. Immunol., 2012, doi: 10.1155 / 2012 / 980250; Marbry and Snavely, IDrugs, 13(8):543-549, 2010). The intramolecular orientation of the VH domain and the VL domain in a scFv is typically not decisive for scFvs. Thus, scFvs with both possible arrangements (VH domain-linker domain-VL domain; VL domain-linker domain-VH domain) may be used.

[0091] In a dsFv, the VH and VL have been mutated to introduce a disulfide bond to stabilize the association of the chains. Diabodies also are included, which are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing tire domains to pair with complementary domains of another chain and creating two antigen binding sites (see, for example, Holliger et al., Proc. Natl. Acad. Sci. U.S.A., 90(14):6444-6448, 1993; Poljak et al., Structure, 2(12):1121-1123, 1994).

[0092] Antibodies also include genetically engineered forms such as chimeric antibodies (such as humanized murine or macaque antibodies) and heteroconjugate antibodies (such as bispecific antibodies).

[0093] Typically, a naturally occurring mammalian immunoglobulin has heavy (H) chains and light (L) chains interconnected by disulfide bonds. Immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as die myriad immunoglobulin variable domain genes. There are two types of light chain, lambda (X) and kappa (K). There are five main heavy chain classes (or isotypes) that determine the functional activity of a mammalian antibody molecule: IgM, IgD, IgG, IgA and IgE.

[0094] Each heavy and light chain contains a constant region (or constant domain) and a variable region (or variable domain). In several aspects, the VHand VLcombine to specifically bind the antigen. In additional aspects, only the VH is required. For example, naturally occurring camelid4239-113261-02

[0095] aiitibodies consisting of a heavy chain only (VHH) are functional and stable in the absence of light chain. Any of the disclosed antibodies can include a heterologous constant domain. For example, the antibody can include a constant domain that is different from a native constant domain, such as a constant domain including one or more modifications (such as tire “LS” mutations) to increase halflife.

[0096] References to “VH” or “VH” refer to the variable region of an antibody heavy chain, including that of an antigen binding fragment, such as Fv, scFv, dsFv or Fab. References to “VL” or “VL” refer to the variable domain of an antibody light chain, including that of an Fv, scFv, dsFv or Fab.

[0097] The VH and VL contain “framework” regions interrupted by three hypervariable regions, also called “complementarity-determining regions” or “CDRs” (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 5thed., NIH Publication No. 91-3242, Public Health Service, National Institutes of Health, U.S. Department of Health and Human Services, 1991). The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three-dimensional space.

[0098] The CDRs are primarily responsible for binding to an epitope of an antigen. The amino acid sequence boundaries of a given CDR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (Sequences of Proteins o f Immunological Interest, U.S. Department of Health and Human Services, 1991; the “Kabat” numbering scheme), Chothia et al. (see Chothia and Lesk, J Mol Biol 196:901-917, 1987; Chothia et al., Nature 342:877 , 1989; and Al-Lazikani et al., JMB 273,927-948, 1997; the “Chothia” numbering scheme), Kunik et al. (see Kunik et al., PLoS Comput Biol 8:el002388, 2012; and Kunik et al., Nucleic Acids Res 40(Web Server issue):W521-524, 2012; “Paratome CDRs”) and the ImMunoGeneTics (IMGT) database (see, Lefranc, Nucleic Acids Res 29:207-9, 2001; the “IMGT” numbering scheme). The Kabat, Paratome and IMGT databases are maintained online. In addition, the AbRSA tool can be used to determine the CDR boundaries according to Kabat, IMGT or Chothia (online at aligncdr.labshare.cn / aligncdr / abrsa.php). The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3 (from tire N-terminus to C-terminus), and are also typically identified by the chain in which the particular CDR is located. Thus, a VH CDR3 is the CDR3 from the VH of die antibody in which it is found, whereas a VL CDR1 is die CDR1 from the VL of the antibody in which it is found. Light chain CDRs are sometimes referred to as LCDR1, LCDR2, and LCDR3. Heavy chain CDRs are sometimes referred to as HCDR1, HCDR2, and HCDR3.

[0099] A “monoclonal antibody” is an antibody obtained from a population of substantially homogeneous antibodies, tiiat is, the individual antibodies comprising die population are identical and / or bind the same epitope, except for possible valiant antibodies, for example, containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which4239-113261-02

[0100] typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates tire character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies are well-known. In some examples, monoclonal antibodies are isolated from a subject. Monoclonal antibodies can have conservative amino acid substitutions which have substantially no effect on antigen binding or other immunoglobulin functions (see, for example, Greenfield (Ed.), Antibodies: A Laboratory Manual, 2nded. New York: Cold Spring Harbor Laboratory Press, 2014.)

[0101] A “humanized” antibody or antigen binding fragment includes a human framework region and one or more CDRs from a non-human (such as a non-human primate, mouse, rat, or synthetic) antibody or antigen binding fragment. The non-human antibody or antigen binding fragment providing the CDRs is termed a “donor,” and the human antibody or antigen binding fragment providing the framework is termed an “acceptor.” Constant regions need not be present, but if they are, they can be substantially identical to human immunoglobulin constant regions, such as at least about 85-90%, such as about 95% or more identical. Hence, all parts of a humanized antibody or antigen binding fragment, except possibly the CDRs, are substantially identical to corresponding parts of natural human antibody sequences.

[0102] A “chimeric antibody” is an antibody that includes sequences derived from two different antibodies, which typically are of different species. In some examples, a chimeric antibody includes one or more CDRs and / or framework regions from one human antibody and CDRs and / or framework regions from another human antibody.

[0103] A “fully human antibody” or “human antibody” is an antibody which includes sequences from (or derived from) the human genome, and does not include sequence from another species. In some aspects, a human antibody includes CDRs, framework regions, and (if present) an Fc region from (or derived from) the human genome. Human antibodies can be identified and isolated using technologies for creating antibodies based on sequences derived from the human genome, for example by phage display or using transgenic animals (see, e.g., Barbas et al. Phage display: A Laboratory Manuel. 1sted. New York: Cold Spring Harbor Laboratory Press, 2004; Lonberg, Nat. Biotechnol., 23(9): 1117-1125, 2005; Lonberg, Curr. Opin. Immunol. 20(4):450-459, 2008).

[0104] Antibody-drug conjugate (ADC): A molecule that includes an antibody (or an antigenbinding fragment of an antibody) conjugated to a drug, such as a cytotoxic agent. ADCs can be used to specifically target a drug to cancer cells through specific binding of the antibody to a tumor antigen4239-113261-02

[0105] expressed on the cell surface. Exemplary drugs for use with ADCs include anti-microtubule agents, such as maytansinoids, auristatin E (e.g., monomethyl auristatin E) and auristatin F, interstrand crosslinking agents or other DNA damaging agents (e.g., pyrrolobenzodiazepines; PDBs), and exatecan.

[0106] Anti-microtubule agent: A type of drug that blocks cell growth by stopping mitosis. Antimicrotubule agents, also referred to as “anti-mitotic agents,’’ are used to treat cancer.

[0107] Binding affinity: Affinity of an antibody for an antigen. In one aspect, affinity is calculated by a modification of the Scatchard method described by Frankel et al., Mol. Immunol., 16:101-106, 1979. In another aspect, binding affinity is measured by an antigen / antibody dissociation rate. In another aspect, a binding affinity is measured by a competition radioimmunoassay. In another aspect, binding affinity is measured by ELISA. In some aspects, binding affinity is measured using bio-layer interferometry (BL1) technology, such as by using the Octet system (Creative Biolabs). In other aspects, Kd is measured using a surface plasmon resonance (SPR) assay, such as by using a BIACORES-2000 or a BIACORES-3000 (BIAcore, Inc., Piscataway, N.J.). In other aspects, antibody affinity is measured by flow cytometry. An antibody that “specifically binds” an antigen (such as GPR124) is an antibody that binds the antigen with high affinity and does not significantly bind other unrelated antigens.

[0108] Bispecific antibody: A recombinant molecule composed of two different antigen binding portions that consequently binds to two different antigenic epitopes. Bispecific antibodies include chemically or genetically linked molecules of two antigen-binding domains. The antigen binding domains can be linked using a linker. The antigen binding domains can be monoclonal antibodies, antigen-binding fragments (e.g., Fab, scFv), or combinations thereof. A bispecific antibody can include one or more constant domains, but does not necessarily include a constant domain. Similarly, a multi- specific antibody is a recombinant protein that includes antigen-binding fragments of at least two different monoclonal antibodies, such as two, three or four different monoclonal antibodies.

[0109] Blood-brain-tumor barrier (BBTB): During tumor progression, the blood-brain barrier (BBB) is disrupted, forming a vascular structure referred to as the BBTB. The BBTB prevents or inhibits the delivery of most drugs and other molecules to tumors in the brain.

[0110] Brain cancer: Any abnormal cell growth in die brain. Exemplary brain cancers include, but are not limited to, glioblastoma, neuroblastoma, chondrosarcoma, medulloblastoma, meningioma, ependymoma, astrocytoma, oligodendroglioma, pituitary adenoma, pituitary carcinoma, craniopharyngioma, mixed glioma, pinealoma, atypical teratoid rhabdoid tumor, hemangioblastoma, germ cell tumor, Schwannoma, choroid plexus tumor, ganglioglioma, chordoma, anaplastic astrocytoma, primary CNS lymphoma and primitive neuroectodermal tumor.

[0111] Brain metastasis: Malignant tumors that originated in another organ or location of the body and subsequendy spread to brain. Examples of tumors that can metastasize to the brain include breast cancer, colon cancer, kidney cancer, lung cancer, melanoma, and thyroid cancer.4239-113261-02

[0112] Chemotherapeutic agent: Any chemical agent with therapeutic usefulness in the treatment of diseases characterized by abnormal cell growth. Such diseases include tumors, neoplasms, and cancer as well as diseases characterized by hyperplastic growth. In one aspect, a chemotherapeutic agent is an agent of use in treating a brain tumor. In one aspect, a chemotherapeutic agent is a radioactive compound. A skilled person can readily identify a chemotherapeutic agent of use (see for example, Slapak and Kufe, Principles of Cancer Therapy, Chapter 86 in Harrison's Principles of Internal Medicine, 14th edition; Perry et al., Chemotherapy, Ch. 17 in Abeloff, Clinical Oncology 2nded., © 2000 Churchill Livingstone, Inc; Baltzer, L., Berkery, R. (eds.f. Oncology Pocket Guide to Chemotherapy, 2nd ed. St. Louis, Mosby-Year Book, 1995; Fischer, D.S., Knobf, M.F., Durivage, H.J. (eds): The Cancer Chemotherapy Handbook, 4th ed. St. Louis, Mosby-Year Book, 1993).

[0113] Combination chemotherapy is the administration of more than one agent to treat cancer. One example is the administration of an antibody or ADC that binds a specific tumor antigen used in combination with a radioactive or chemical compound. In one example, a chemotherapeutic agent is a biologic, such as a therapeutic antibody (e.g., therapeutic monoclonal antibody), such as anti-PDl or anti-PDLl (e.g., pembrolizumab and nivolumab), anti-CTLA4 (e.g., ipilimumab), anti-EGFR (e.g., cetuximab), anti-VEGF (e.g., bevacizumab), or combinations thereof (e.g., anti-PD-1 and anti-CTLA-4).

[0114] Chimeric antigen receptor (CAR): A chimeric molecule that includes an antigen-binding portion (such as a scFv) and a signaling domain, such as a signaling domain from a T cell receptor (e.g. CD3 . Typically, CARs are comprised of an antigen-binding moiety, a hinge region, a transmembrane domain and an endodomain. The endodomain typically includes a signaling chain having an immunoreceptor tyrosine-based activation motif (IT AM), such as CD3^ or FceRIy. In some instances, the endodomain further includes the intracellular portion of at least one additional costimulatory signaling domain, such as CD28, 4-1BB (CD137), ICOS, 0X40 (CD134), CD27 and / or DAP10.

[0115] Codon-optimized: A nucleic acid molecule encoding a protein can be codon-optimized for expression of the protein in a particular organism by including the codon most likely to encode a particular amino acid at each position of the sequence. Codon usage bias is the difference in the frequency of occurrence of synonymous codons (encoding the same amino acid) in coding DNA. A codon is a series of three nucleotides (a triplet) that encodes a specific amino acid residue in a polypeptide chain or for the termination of translation. There are 20 different naturally-occurring amino acids, but 64 different codons (61 codons encoding for amino acids plus 3 stop codons). Thus, there is degeneracy because one amino acid can be encoded by more than one codon. A nucleic acid sequence can be optimized for expression in a particular organism (such as a human) by evaluating the codon usage bias in that organism and selecting the codon most likely to encode a particular amino acid. Multivariate statistical methods, such as correspondence analysis and principal component analysis, are widely used to analyze variations in codon usage. Computer programs are4239-113261-02

[0116] available to implement the statistical analyses related to codon usage, such as Codon W, GCUA, and INCA.

[0117] Complementarity determining region (CDR): Amino acid sequences which together define the binding affinity and specificity of tire natural Fv region of a native Ig binding site. The light and heavy chains of an Ig each have three CDRs, designated LCDR1, LCDR2, LCDR3 and HCDR1, HCDR2 and HCDR3, respectively. A single-domain antibody has three CDRs, referred to as CDR1, CDR2 and CDR3.

[0118] Conjugate: In the context of the present disclosure, a “conjugate” is an antibody or antibody fragment (such as an antigen-binding fragment) covalently linked to an effector molecule or a second protein (such as a second antibody). The effector molecule can be, for example, a drug, toxin, therapeutic agent, detectable label, protein, nucleic acid, lipid, nanoparticle, carbohydrate, PROTAC, or recombinant virus. An antibody conjugate is often referred to as an “immunoconjugate.” When the conjugate includes an antibody linked to a chug (e.g., a cytotoxic agent), the conjugate is often referred to as an “antibody-drug conjugate” or “ADC.” Other antibody conjugates include, for example, multi-specific (such as bispecific or trispecific) antibodies, chimeric antigen receptors (CARs) and antibody-PROTAC conjugates.

[0119] Conservative amino acid substitution: “Conservative” amino acid substitutions are those substitutions that do not substantially affect a function of a protein, such as the ability of the protein to interact with a target protein.

[0120] In some aspects, a conservative amino acid substitution in an anti-GPR124 antibody is one that does not reduce binding of the antibody to GPR124 by more than 10% (such as by more than 5%) compared to the GPR124 binding of the corresponding antibody lacking the conservative amino acid substitution. In some aspects, the anti-GPR124 antibody can include up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10 conservative substitutions compared to a reference antibody and retain specific binding activity for GPR124, and / or retain the ability to promote delivery of drugs across the BBTB.

[0121] Typically, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (for instance less than 5%, in some aspects less than 1%) in an encoded sequence are conservative variations where the alterations result in the substitution of an amino acid with a chemically similar amino acid. The following six groups are examples of amino acids that are considered to be conservative substitutions for one another:

[0122] 1) Alanine (A), Serine (S), Threonine (T);

[0123] 2) Aspartic acid (D), Glutamic acid (E);

[0124] 3) Asparagine (N), Glutamine (Q);

[0125] 4) Arginine (R), Lysine (K);

[0126] 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and

[0127] 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

[0128] Cytotoxic agent: Any drug or compound that kills cells.4239-113261-02

[0129] Degenerate variant: A polynucleotide encoding a protein (for example, an antibody or portion thereof, such as a variable region, that binds GPR124) that includes a sequence that is degenerate as a result of the genetic code. There are twenty natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included as long as tlie amino acid sequence of die antibody encoded by die nucleotide sequence is unchanged.

[0130] Disease or disorder of the central nervous system (CNS): Any pathological condition that primarily affects the CNS, such as the brain. In some aspects herein, the disease or disorder of the CNS is a brain cancer (such as glioblastoma, neuroblastoma, chondrosarcoma, medulloblastoma, meningioma, ependymoma, astrocytoma, oligodendroglioma, pituitary adenoma, pituitary carcinoma, craniopharyngioma, mixed glioma, pinealoma, atypical teratoid rhabdoid tumor, hemangioblastoma, germ cell tumor, Schwannoma, choroid plexus tumor, ganglioglioma, chordoma, anaplastic astrocytoma, primary CNS lymphoma and primitive neuroectodermal tumor) or a brain metastasis (such as a breast cancer, colon cancer, kidney cancer, lung cancer, melanoma, or thyroid cancer metastasis). Other exemplary diseases or disorders of the CNS include, but are not limited to, epilepsy, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, stroke, meningitis, encephalitis, cerebral palsy, Huntington disease, Bell’s palsy, Lewy body dementia, and cerebrovascular disease.

[0131] Drug: Any agent or compound used to treat, ameliorate or prevent a disease or condition in a subject. In some aspects herein, the drug is an anti-cancer agent, for example a cytotoxic agent, such as an anti-mitotic or anti-microtubule agent.

[0132] Effective amount (or therapeutically effective amount): A quantity of a specific substance sufficient to achieve a desired effect in a subject to whom the substance is administered. For instance, this can be the amount of anti-GPR124 antibody (or conjugate thereof) necessary to promote delivery of a drug across the BBTB.

[0133] In some aspects, an effective amount of a disclosed antibody that binds to GPR124 is an amount necessary to increase delivery of a drug (such as an ADC, CAR T cell, or chemotherapeutic agent) across the BBTB by a desired amount, for example by at least 5%, at least 10%, at least 20%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100%, as compared to a suitable control.

[0134] The effective amount (or therapeutically effective amount) of an antibody disclosed herein that is administered to a subject to enhance drug delivery will vary depending upon a number of factors associated with that subject, for example the overall health and / or weight of the subject. An effective amount can be determined by varying the dosage and measuring the resulting response. Effective amounts also can be determined through various in vitro, in vivo or in situ immunoassays.

[0135] An effective or therapeutically effective amount encompasses a fractional dose that contributes in combination with previous or subsequent administrations to attaining an effective response. For example, an effective amount of an agent can be administered in a single dose, or in4239-113261-02

[0136] several doses, for example daily, during a course of treatment lasting several days or weeks.

[0137] However, the effective amount can depend on the subject being treated, the severity and type of the condition being treated, and the manner of administration. A unit dosage form of an antibody or bispecific antibody can be packaged in an amount, or in multiples of the effective amount, for example, in a vial (e.g., with a pierceable lid) or syringe having sterile components.

[0138] Effector molecule: The portion of a chimeric molecule that is intended to have a desired effect on a cell to which the chimeric molecule is targeted. Effector molecule is also known as an effector moiety (EM), therapeutic agent, or diagnostic agent, or similar terms. Therapeutic agents (or drugs) include such compounds as nucleic acids, proteins, peptides, amino acids or derivatives, glycoproteins, radioisotopes, lipids, carbohydrates, or recombinant viruses. Nucleic acid therapeutic and diagnostic moieties include antisense nucleic acids, derivatized oligonucleotides for covalent cross-linking with single or duplex DNA, and triplex forming oligonucleotides. Alternatively, the molecule linked to a targeting moiety, such as an anti-GPR124 antibody, may be an encapsulation system, such as a liposome or micelle that contains a therapeutic composition such as a drug, a nucleic acid (such as an antisense nucleic acid), or another therapeutic moiety that can be shielded from direct exposure to the circulatory system. Means of preparing liposomes attached to antibodies are well known to those of skill in the art (see, for example, U.S. Patent No. 4,957,735; and Connor et al., Pharm Ther 28:341-365, 1985). Diagnostic agents or moieties include radioisotopes and other detectable labels. Detectable labels useful for such purposes are also well known, and include radioactive isotopes such as35S,nC,13N,150,18F,19F,99mTc,1311,3H,14C,15N,90Y, "Tc,niIn and125I, fluorophores, chemiluminescent agents, and enzymes.

[0139] Framework region: Amino acid sequences interposed between CDRs. Framework regions include variable light and variable heavy framework regions.

[0140] Fusion protein: A protein that includes at least a portion of two different (heterologous) proteins. In some aspects herein, the fusion protein is an antigen-binding fragment of a monoclonal antibody fused to an Fc protein.

[0141] G protein-coupled receptor 124 (GPR124): An orphan receptor in the adhesion family of G protein-coupled receptors (GPCRs). GPR124 is involved in the canonical Wnt signaling pathway and plays a role in maintaining blood-brain barrier (BBB) integrity in CNS disease. This protein is located in intracellular membrane -bound organelles and the plasma membrane. GPR124 is upregulated in endothelial cells during tumor and physiologic angiogenesis. GPR125 is also known as tumor endothelial marker 5 (TEM5) and adhesion G protein-coupled receptor A2 (ADGRA2). Nucleotide and amino acid sequences of GPR124 are publicly available (see, e.g., NCBI Gene ID 25960).

[0142] Heterologous: Originating from a separate genetic source or species. For example, a promoter can be heterologous to an operably linked nucleic acid sequence.4239-113261-02

[0143] IgG: A polypeptide belonging to the class or isotype of antibodies that are substantially encoded by a recognized immunoglobulin gamma gene. In humans, this class includes IgGi, IgGi, IgG i, and IgG4. In mice, this class includes IgGi, IgGi,, IgGib, IgGi.

[0144] Immunoconjugate: A covalent linkage of an effector molecule to an antibody or functional fragment thereof. The effector molecule can be a detectable label or an immunotoxin. Specific, nonlimiting examples of toxins include, but are not limited to, abrin, ricin, Pseudomonas exotoxin (PE, such as PE35, PE37, PE38, and PE40), diphtheria toxin (DT), botulinum toxin, or modified toxins thereof, or other toxic agents that directly or indirectly inhibit cell growth or kill cells. For example, PE and DT are highly toxic compounds that typically bring about death through liver toxicity. PE and DT, however, can be modified into a form for use as an immunotoxin by removing the native targeting component of the toxin (such as the domain la of PE and the B chain of DT) and replacing it with a different targeting moiety, such as an antibody.

[0145] Immunoliposome: A liposome with antibodies or antibody fragments conjugated to its surface. Immunoliposomes can carry cytotoxic agents or other drugs to antibody-targeted cells, such as tumor cells.

[0146] Interstrand crosslinking agent: A type of cytotoxic drug capable of binding covalently between two strands of DNA, thereby preventing DNA replication and / or transcription.

[0147] Isolated: A biological component (such as a nucleic acid, peptide, protein or protein complex, for example an antibody) that has been substantially separated, produced apart from, or purified away from other biological components in the cell of the organism in which the component occurs, that is, other chromosomal and extra-chromosomal DNA and RNA, and proteins. Thus, isolated nucleic acids, peptides and proteins include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids, peptides and proteins prepared by recombinant expression in a host cell, as well as chemically synthesized nucleic acids. An isolated nucleic acid, peptide or protein, for example an antibody, can be at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% pure.

[0148] Label: A detectable compound or composition that is conjugated directly or indirectly to another molecule, such as an antibody (such as one provided herein), to facilitate detection of that molecule. Specific, non-limiting examples of labels include fluorescent tags, enzymatic linkages, and radioactive isotopes. In one example, a “labeled antibody” refers to incorporation of another molecule in the antibody. For example, the label is a detectable marker, such as the incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (for example, streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). Various methods of labeling polypeptides and glycoproteins may be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionucleotides (such as35S,nC,13N,150,18F,19F,99mTc,1311,3H,14C,4239-113261-02

[0149] 15N,90Y, ”TC,inIn and125I), fluorescent labels (such as fluorescein isothiocyanate (FITC), rhodamine, lanthanide phosphors), enzymatic labels (such as horseradish peroxidase, betagalactosidase, luciferase, alkaline phosphatase), chemiluminescent markers, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (such as a leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags), or magnetic agents, such as gadolinium chelates. In some aspects, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.

[0150] Linker: A peptide or other molecule that joins two proteins. In some aspects herein, the linker is a peptide within an antibody binding fragment (such as an Fv fragment) which serves to indirectly bond the variable heavy chain to the variable light chain. “Linker” can also refer to a peptide serving to link a targeting moiety, such as an antibody, to an effector molecule, such as a cytotoxin or a detectable label. The terms “conjugating,” “joining,” “bonding” or “linking” refer to making two polypeptides into one contiguous polypeptide molecule, or to covalently attaching a radionuclide or other molecule to a polypeptide, such as an scFv. In the specific context, the terms include reference to joining a ligand, such as an antibody moiety, to an effector molecule. The linkage can be either by chemical or recombinant means. “Chemical means” refers to a reaction between the antibody moiety and the effector molecule such that there is a covalent bond formed between the two molecules to form one molecule.

[0151] Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and where necessary to join two protein-coding regions, in the same reading frame.

[0152] Pharmaceutically acceptable carriers: The pharmaceutically acceptable carriers of use are conventional. Remington: The Science and Practice of Pharmacy, 23rded., Academic Press, 2020, describes compositions and formulations suitable for pharmaceutical delivery of the disclosed antibodies. In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually include injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, added preservatives (such as nonnatural preservatives), and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate. In particular examples, the pharmaceutically acceptable carrier is sterile and suitable for4239-113261-02

[0153] parenteral administration to a subject for example, by injection. In some aspects, the active agent and pharmaceutically acceptable carrier are provided in a unit dosage form such as a pill or in a selected quantity in a vial. Unit dosage forms can include one dosage or multiple dosages (for example, in a vial from which metered dosages of the agents can selectively be dispensed).

[0154] Proteolysis targeting chimera (PROTAC): A type of molecule designed to selectively and efficiently degrade specific target proteins within a cell. Instead of directly inhibiting a protein, PROTACs harness the cell’s natural protein degradation machinery, tine ubiquitin-proteasome system, to eliminate the target protein. They work by binding both to die target protein (e.g., GPR124 or a downstream signaling component, such as P-catenin) and to an E3 ubiquitin ligase, marking the target protein for degradation. PROTACs are composed of three key components: a ligand that binds to the protein of interest (POI), a ligand that binds to an E3 ubiquitin ligase, and a linker that connects the two ligands. These components work together to bring the POI into close proximity with the E3 ubiquitin ligase, leading to the ubiquitination and subsequent degradation of the target protein by the proteasome. PROTACs can be conjugated to antibodies to selectively deliver the PROTACs to specific cells types (see, e.g., Chan et al., Bioconjugate Chem 34(11):2049-2054, 2023; Maneiro et al., ACS Chem Biol 15:1306-1312, 2020).

[0155] Pyrrolobenzodiazepine (PBD): A class of sequence-selective DNA minor-groove binding crosslinking agents originally discovered in Streptomyces species. PDBs are significantly more potent than systemic chemotherapeutic drugs. The mechanism of action of PBDs is associated with their ability to form an adduct in tire minor groove of DNA, thereby interfering with DNA processing. In the context of the present disclosure, PBDs include naturally produced and isolated PBDs, chemically synthesized naturally occurring PBDs, and chemically synthesized non-naturally occurring PBDs. PBDs also include monomeric, dimeric and hybrid PBDs (for a review see Gerratana, Med Res Rev 32(2):254-293, 2012). In some aspects, tire PBD binds a single strand of DNA; these forms of PBD are referred to herein as “DNA damaging agents” as they do not lead to crosslinking of DNA.

[0156] Sequence identity: The similarity between amino acid or nucleic acid sequences is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. Homologs or variants of a polypeptide or nucleic acid molecule will possess a relatively high degree of sequence identity when aligned using standard methods.

[0157] Methods of alignment of sequences for comparison are well-known. Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl. Math. 2(4):482-489, 1981; Needleman and Wunsch, J. Mol. Biol. 48(3):443-453, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85(8):2444-2448, 1988; Higgins and Sharp, Gene, 73(l):237-244, 1988; Higgins and Sharp, Bioinformatics. 5(2): 151-3, 1989; Corpet, Nucleic Acids Res. 16(22): 10881-10890, 1988; Huang et al. Bioinformatics, 8(2): 155-165, 1992; and Pearson, Methods Mol. Biol. 24:307-331, 1994.4239-113261-02

[0158] Altschul et al., J. Mol. Biol. 215(3):403-410, 1990, presents a detailed consideration of sequence alignment methods and homology calculations. Unless otherwise specified, percentage sequence identity between sequences is determined by pairwise alignment over tire full-length of the reference sequence using an appropriate global alignment algorithm, such as tire Needleman-Wunsch algorithm as implemented in EMBOSS program stretcher for longer sequences such as genomic genome sequences and as implemented in EMBOSS program needle for shorter sequences (e.g., protein sequences and nucleic acid sequences less than lOkb), typically with default gap penalties and scoring matrix. Alternative alignment programs and parameters may also be used.

[0159] Homologs and variants of a VLor a VH of an antibody that specifically binds GPR124, or a fragment thereof, are typically characterized by possession of at least about 75%, for example at least about 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity counted over the full length alignment with the amino acid sequence of the antibody, such as using EMBOSS program needle set to default parameters. Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0160] Specifically bind: When referring to an antibody, refers to a binding reaction that determines the presence of a target protein in the presence of a heterogeneous population of proteins and other biologies. Thus, under designated conditions, an antibody binds preferentially to a particular target protein, peptide or polysaccharide (such as GPR124) and does not bind in a significant amount to other proteins present in the sample or subject. Specific binding can be determined by methods known in the art. See Greenfield (Ed.), Antibodies: A Laboratory Manual, 2nded. New York: Cold Spring Harbor Laboratory Press, 2014, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.

[0161] An antibody (or antigen-binding fragment) that specifically binds to an epitope on GPR124 is an antibody that binds substantially to GPR124, including cells or tissue expressing GPR124, substrates to which the GPR124 protein is attached, or GPR124 in a biological specimen. It is recognized that a certain degree of non-specific interaction may occur between an antibody and a nontarget (such as a cell that does not express GPR124). Typically, specific binding results in a much stronger association between the antibody and protein or cells bearing the antigen than between the antibody and protein or cells lacking the antigen. Specific binding typically results in greater than 2-fold, such as greater than 5-fold, greater than 10-fold, or greater than 100-fold increase in the amount of bound antibody (per unit time) to a protein including the epitope or cell or tissue expressing the target epitope as compared to a protein or cell or tissue lacking this epitope. Specific binding to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. A variety of immunoassay formats (e.g., ELISA, BLI, SPR and flow cytometry) are appropriate for selecting antibodies or other ligands specifically immunoreactive with a particular protein.4239-113261-02

[0162] Subject: Living multicellular vertebrate organisms, a category that includes human and nonhuman mammals. In some examples, die subject is a human. In some examples, the subject has a disease or disorder of the CNS, such as a brain tumor.

[0163] Synthetic: Produced by artificial means in a laboratory, for example a synthetic nucleic acid or protein (for example, an antibody) can be chemically syndiesized in a laboratory.

[0164] Toxin: A molecule tiiat is cytotoxic for a cell. Toxins include abrin, ricin, Pseudomonas exotoxin (PE), diphtheria toxin (DT), botulinum toxin, saporin, restrictocin or gelonin, or modified toxins thereof. For example, PE and DT are highly toxic compounds that typically bring about death through liver toxicity. PE and DT, however, can be modified into a form for use as an immunotoxin by removing die native targeting component of the toxin (such as domain la of PE or the B chain of DT) and replacing it with a different targeting moiety, such as an antibody.

[0165] Vector: An entity containing a nucleic acid molecule (such as a DNA or RNA molecule) bearing a promoter(s) that is operationally linked to the coding sequence of a protein of interest and can express the coding sequence. Non-limiting examples include a naked or packaged (lipid and / or protein) DNA, a naked or packaged RNA, a subcomponent of a virus or bacterium or other microorganism that may be replication-incompetent, or a virus or bacterium or other microorganism that may be replication-competent. A vector is sometimes referred to as a construct. Recombinant DNA vectors are vectors having recombinant DNA. A vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector can also include one or more selectable marker genes and other genetic elements known in the art. Viral vectors are recombinant nucleic acid vectors having at least some nucleic acid sequences derived from one or more viruses. In some aspects, a viral vector comprises a nucleic acid molecule encoding a disclosed antibody that binds (such as specifically binds) to GPR124. Viral vectors include, but are not limited to, lentiviral vectors, adenovirus vectors and adeno-associated virus (AAV) vectors.

[0166] III. Introduction

[0167] The vasculature in the normal CNS is lined by a tightly sealed layer of endothelium that plays a major role in controlling the blood-brain barrier (BBB). While the neovasculature of brain tumors is typically more permeable (e.g., fenestrated) than that of surrounding normal brain tissue, brain tumor vasculature maintains heterogenous BBB properties, including an array of drug efflux pumps mostly absent from non-CNS vasculature (Arvanitis et al., Nat Rev Cancer 20:26-41, 2020; Adkins et al., Front Pharmacol 4:136, 2013; de Gooijer et al., Cell Rep Med 2:100184, 2021). The partial / residual barrier is known as the blood-brain tumor barrier (BBTB) or the blood tumor barrier (Arvanitis et al., Nat Rev Cancer 20:26-41, 2020; Adkins et al., Front Pharmacol 4:136, 2013). The brain tumor vasculature, which controls the BBTB, maintains some of the BBB properties of the surrounding normal brain vasculature from which it originates. The BBTB continues to be a major hurdle for drug delivery and successful treatment of both primary brain tumors and brain metastases clinically4239-113261-02

[0168] (Arvanitis et al., Nat Rev Cancer 20:26-41, 2020; Steeg, Nat Rev Clin Oncol 18:696-714, 2021; Sarkaria et al., Neuro Oncol 20:184-191, 2018).

[0169] The present disclosure sought to create and test antagonistic GPR124 monoclonal antibodies (mAbs) that can enhance drug delivery to brain tumors. Using genetically engineered Gprl24 conditional KO mice, a previous study established GPR124 as a cell surface protein required for the barrier properties of brain tumor endothelium, but not of normal adult brain endothelium (Chang, et al., Nat Med 23:450-460, 2017). Based on this finding, it was hypothesized that GPR124 could be exploited for tire rational design of therapeutic agents that facilitate BBTB permeability without compromising the normal BBB. Using Gprl24 global and endothelial-specific KO mice, GPR124 had previously been found to be required for the establishment of the BBB during CNS development through its ability to selectively activate Wnt7-mediated canonical P-catenin signaling in brain endothelium (Cullen et al., Proc Natl Acad Sci USA 108:5759-5764, 2011; Posokhova et al., Cell Rep 10:123-130, 2015; Zhou and Nathans, Dev Cell 31:248-256, 2014). Later, RECK and Frizzled receptors were also found to complex with GPR124 and Wnt7 at the cell surface to mediate P-catenin signaling (Eubelen et al., Science 361(6403):eaatll78, 2018; Cho etal., Neuron 95:1221-1225, 2017). While a key role for the Wnt7-GPR124- -catenin axis in establishing the BBB during developmental angiogenesis is well understood, it has been determined that GPR124 is not essential for maintaining the BBB in the quiescent vessels of adult CNS (Chang, et al., Nat Med 23:450-460, 2017). Because low GPR124 levels can be detected in normal adult brain endothelial cells (ECs) (Cullen et al., Proc Natl Acad Sci USA 108:5759-5764, 2011), it suggests there may be other redundant factors that help ensure maintenance of normal BBB after it has been established, which compensate for the loss of GPR124 in normal brain ECs. A likely redundant pathway is the Norrin / TSPAN12 / -catenin pathway which is active in normal brain endothelium and appears to maintain P-catenin signaling upon GPR124 loss (Wang et al., Proc Natl Acad Sci USA 115:E11827-E11836, 2018; Zhou etal., J Clin Invest 124:3825-3846, 2014; and Cho et al., Neuron 95:1221-1225, 2017). Importantly, in brain tumors, GPR124 was found to play an indispensable role in promoting the establishment of the BBTB in tumor neovasculature (Chang, et al., Nat Med 23:450-460, 2017), mirroring its important role in embryonic barrier formation in the angiogenic blood vessels of tire developing CNS (Cullen et al., Proc Natl Acad Sci USA 108:5759-5764, 2011). Using tracer studies and Gprl24 conditional KO mice, it was verified that GPR124 plays an indispensable role in regulating vessel permeability in adult GL261 glioma tumors, but not in surrounding normal brain vasculature.

[0170] While blockade of the BBTB using antagonists of Wnt, GSK and other players in the P-catenin signaling pathway has long been considered, side effects are a major concern as Wnt-P-catenin signaling regulates a multitude of normal physiological processes (Kahn, Nat Rev Drug Discov 13:513-532, 2014). However, GPR124 is highly unique in that it appears to be a specific and essential co-activator of Wnt7-P-catenin signaling in proliferating brain endothelium, providing a selective target that can potentially be exploited to manipulate the BBTB without impacting other4239-113261-02

[0171] extracranial Wnt-0-catenin signaling pathways (Posokhova et al., Cell Rep 10:123-130, 2015; Zhou and Nathans, Dev Cell 31:248-256, 2014). Based on these findings, the present disclosure describes studies to determine if GPR124 blockade can be exploited as a strategy to transiently and selectively open the BBTB of tumors in the brain. This, in turn, can help with the delivery of antibody-drug conjugates (ADCs) and other therapies (such as CAR T cells and chemotherapeutic agents) to any type of primary brain tumor, such as gliomas, glioblastomas, astrocytomas, meningiomas, oligodendrogliomas, medulloblastomas, and neuroblastomas, as well as brain metastases from breast cancers, lung cancers, colon cancers or melanomas. Furthermore, because GPR124 also plays an essential role in BBB during stroke (Chang, et al., Nat Med 23:450-460, 2017), and potentially other cerebrovascular diseases where aberrant Wnt / 0-catenin signaling is a common feature, GPR124 targeted agents (agonists or antagonists) could be extended to a variety of other neurological diseases. While genetic studies in mice implicate GPR124 as a promising target for increasing the permeability of the BBTB, therapeutic agents that can antagonize GPR124 function have not yet been developed.

[0172] To effectively target brain tumors, an ideal ADC therapy needs to overcome the BBTB and bind target expressing cells in a highly selective manner, with minimal off-target binding. Many strategies to improve drug delivery to brain tumors are under clinical evaluation, such as tight junction-modulating agents, inhibitors of drug efflux transporters, and receptor-mediated transcytosis. However, one concern with these approaches is enhanced toxicities caused by increased permeability across the normal BBB. Other strategies such as convection-enhanced delivery, require invasive catheterization, and like focused ultrasound or thermal ablation therapy, can potentially miss undetectable microlesions invading throughout the brain (Steeg, Nat Rev Clin Oncol 18:696-714, 2021).

[0173] Activation of 0-catenin signaling is known to be essential for promoting barrier properties of proliferating brain endothelium (Posokhova et al., Cell Rep 10:123-130, 2015; Noda et al., Cancer Sci 107:576-582, 2016). However, Wnt / GSK / 0-catenin signaling is widespread during normal physiology, making tumor selective targeting challenging. The discovery that GPR124 is an essential co-receptor that is critical for activation of Wnt7-0-catenin signaling and barrier properties in proliferating brain tumor endothelium, but not normal quiescent brain endothelium (Chang, et al., Nat Med 23:450-460, 2017), provides an opportunity for selective opening of the BBTB, without impacting the normal BBB.

[0174] IV. Monoclonal Antibodies Targeted to GPR124

[0175] Disclosed herein are GPR124-targeted human monoclonal antibodies, T502 and T519, isolated from a human scFv phage library. The anti-GPR124 antibodies bind both human and mouse GPR124 with high affinity, exhibit inhibitory activity against GPR124, and block Wnt7 / p-catenin signaling. The disclosed GPR124-targeted antibodies can be used, for example, to enhance the delivery of therapeutic agents across the BBTB, or to inhibit / reduce tumor vasculature.4239-113261-02

[0176] The variable heavy (VH) and variable light (VL) domain sequences of T502 and T519 are provided below. The CDR sequences according to Kabat are underlined. The tables following each VH and VL domain sequence provide the CDR sequences as determined by IMGT, Kabat and Chothia.

[0177] T502 VH domain (SEQ ID NO: 1) OVOLVOSGAEVKKPGSSVKVSCKASGGTFSSYAISWVROAPGOGLEWMGRIIPILGIANYAO KFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGGYSGYDYDAFDIWGOGTMVTVSS

[0178] Scheme CDR Sequence SEQ ID NO:

[0179] IMGT HCDR1 GGTFSSYA 5

[0180] IMGT HCDR2 IIPILGIA 6

[0181] IMGT HCDR3 ARGGYSGYDYDAFDI 7

[0182] Kabat HCDR1 SYAIS 8

[0183] Kabat HCDR2 RIIPILGIANYAQKFQG 9

[0184] Kabat HCDR3 GGYSGYDYDAFDI 10

[0185] Chothia HCDR1 GGTFSSY 11

[0186] Chothia HCDR2 IPILGI 12

[0187] Chothia HCDR3 GGYSGYDYDAFDI 10

[0188]

[0189] T502 VL domain (SEQ ID NO: 2) QPVLTQPPSVSVAPGKTARITCGGRNIGFKTVHWYQQKPGQAPGLVIYYDNDRPSGIPKRFSG SNSGNTATLTISRVEAGDEADYYCOVWDNSIDHFVFGTGTKVTVL

[0190] Scheme CDR Sequence SEQ ID NO:

[0191] IMGT LCDR1 NIGFKT 13

[0192] IMGT LCDR2 YDN 14

[0193] IMGT LCDR3 QVWDNSIDHFV 15

[0194] Kabat LCDR1 GGRNIGFKTVH 16

[0195] Kabat LCDR2 YDNDRPS 17

[0196] Kabat LCDR3 QVWDNSIDHFV 15

[0197] Chothia LCDR1 GGRNIGFKTVH 16

[0198] Chothia LCDR2 YDNDRPS 17

[0199] Chothia LCDR3 QVWDNSIDHFV 15

[0200]

[0201] 4239-113261-02

[0202] T519 VH domain (SEQ ID NO: 3) OVQLVESGGGVVEPGRSLTLSCAASGFTFDDYAMHWVRQVPGKGLEWVSGISSNRGSLDYA DSVKGRFTISRDNAKNTLYLQMNSLRTEDTAVYYCGRGGTVITSYYDPIDVWGOGTTVTVSS

[0203] Scheme CDR Sequence SEQ ID NO:

[0204] IMGT HCDR1 GFTFDDYA 18

[0205] IMGT HCDR2 ISSNRGSL 19

[0206] IMGT HCDR3 GRGGTVITSYYDPIDV 20

[0207] Kabat HCDR1 DYAMH 21

[0208] Kabat HCDR2 GISSNRGSLDYADSVKG 22

[0209] Kabat HCDR3 GGTVITSYYDPIDV 23

[0210] Chothia HCDR1 GFTFDDY 24

[0211] Chothia HCDR2 SSNRGS 25

[0212] Chothia HCDR3 GGTVITSYYDPIDV 26

[0213]

[0214] T519 VL domain (SEQ ID NO: 4) QAGLTOPPSVSVAPGKTARITCGGRNIGFKTVHWYQQKPGQAPGLVIYYDNDRPSGIPKRFS GSNSGNTATLTISRVEAGDEADYYCOVWDNSIDHFVFGTGTKVTVL

[0215] Scheme CDR Sequence SEQ ID NO:

[0216] IMGT LCDR1 NIGFKT 13

[0217] IMGT LCDR2 YDN 14

[0218] IMGT LCDR3 QVWDNSIDHFV 15

[0219] Kabat LCDR1 GGRNIGFKTVH 16

[0220] Kabat LCDR2 YDNDRPS 17

[0221] Kabat LCDR3 QVWDNSIDHFV 15

[0222] Chothia LCDR1 GGRNIGFKTVH 16

[0223] Chothia LCDR2 YDNDRPS 17

[0224] Chothia LCDR3 QVWDNSIDHFV 15

[0225]

[0226] Provided herein are monoclonal antibodies that bind (such as specifically bind) G protein-coupled receptor 124 (GPR124), such as human and / or mouse GPR124. In some aspects, the monoclonal antibody includes at least a portion of an amino acid sequence set forth herein as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, such as one or more (such as one, two or three) CDR sequences of a variable domain of antibody T502 or T519. The CDR sequences can be determined using any numbering scheme, including but not limited to, IMGT, Kabat or Chothia.4239-113261-02

[0227] In some aspects, the monoclonal antibody includes a variable heavy (VH) domain having a heavy chain complementarity determining region 1 (HDR1), a HCDR2 and a HCDR3, and a variable light (VL) domain having a light chain complementarity determining region 1 (LDR1), a LCDR2 and a LCDR3, wherein tire VH domain includes the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 1 and the VL domain includes the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 2; or the VH domain includes the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 3 and the VL domain includes the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 4.

[0228] In some examples, the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 respectively include SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7, and / or the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 respectively include SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.

[0229] In other examples, the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 respectively include SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, and / or the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 respectively include SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 15.

[0230] In other examples, the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 respectively include SEQ ID NO: 11 , SEQ ID NO: 12 and SEQ ID NO: 10, and / or the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 respectively include SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 15.

[0231] In other examples, the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 respectively include SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, and / or the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 respectively include SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.

[0232] In other examples, the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 respectively include SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23, and / or the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 respectively include SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 15.

[0233] In yet other examples, the amino acid sequences of the HCDR1 , the HCDR2 and the HCDR3 respectively include SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26, and / or the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 respectively include SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 15.

[0234] In particular examples, the amino acid sequence of the VH domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1 and includes the HCDR1, HCDR1 and HCDR3 sequences of SEQ ID NO: 1; and / or the amino acid sequence of the VL domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 2 and includes the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 2.4239-113261-02

[0235] In other particular examples, the amino acid sequence of the VH domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 3 and includes the HCDR1, HCDR1 and HCDR3 sequences of SEQ ID NO: 3; and / or the amino acid sequence of tire VL domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 4 and includes the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 4.

[0236] In specific non-limiting examples, the amino acid sequence of the VH domain includes or consists of SEQ ID NO: 1 and / or the amino acid sequence of the VL domain includes or consists of SEQ ID NO: 2. In another specific non-limiting example, the amino acid sequence of the VH domain includes or consists of SEQ ID NO: 3 and / or the amino acid sequence of the VL domain comprises or consists of SEQ ID NO: 4.

[0237] In some aspects, the monoclonal antibody is a human monoclonal antibody.

[0238] In some aspects, the monoclonal antibody is an antigen-binding fragment of an antibody, such as a single chain variable fragment (scFv) or a fragment antigen-binding (Fab).

[0239] In other aspects, the monoclonal antibody is an IgG, such as a human IgG. In some examples, the IgG is an IgGl, IgG2, IgG3 or IgG4.

[0240] In some aspects, the monoclonal antibody enhances delivery of a therapeutic agent across the blood-brain-tumor barrier (BBTB). For example, the therapeutic agent can be an anti-tumor therapy, such as an antibody-drug conjugate (ADC), a chimeric antigen receptor (CAR)-expressing immune cell (e.g., a CAR T cell), or an immunotoxin targeted to tumor cells. In other examples, the therapeutic agent is a chemotherapy drug. Enhancing delivery of the therapeutic agent can improve the therapeutic index of the therapeutic agent. In some instances, the monoclonal antibody enhances delivery of the therapeutic agent with little to no toxicity to healthy tissues / cells.

[0241] Also provided herein are fusion proteins that include a monoclonal antibody disclosed herein and a heterologous protein. In some aspects, the heterologous protein is linker or a protein tag. In some examples, the fusion protein includes a scFv or Fab of a monoclonal antibody disclosed herein fused to a Fc protein, such as a human or mouse Fc protein.

[0242] Further provided herein are multi-specific antibodies that include a monoclonal antibody disclosed herein and at least one additional monoclonal antibody. In some aspects, the multi-specific antibody is a bispecific antibody. In other aspects, the multi- specific antibody is a trispecific antibody. Multi-specific antibodies are further described in section V.

[0243] Also provided herein are chimeric antigen receptors (CARs) that include a monoclonal antibody disclosed herein. In some aspects, the CAR further includes a hinge region, a transmembrane domain, an intracellular co-stimulatory signaling domain, an intracellular signaling domain, or any combination thereof. In some examples, the hinge region includes a CDS, a CD28, or an IgG4 hinge region, the transmembrane domain includes a CD8 or a CD28 transmembrane domain, the intracellular co-stimulatory signaling domain includes a CD28 or a 4- IBB signaling domain4239-113261-02

[0244] aiid / or the intracellular signaling domain includes a CD3^ signaling domain. Further provided are isolated cells that express a GPR124-targeted CAR disclosed herein. In some aspects, the cell is an immune cell or an induced pluripotent stem cell (iPSC). In some examples, the immune cell is a T cell, a natural killer (NK) cell, a B cell, or a macrophage. CARs and CAR-expressing cells are further described in section VI.

[0245] Also provided herein are immunoconjugates that include a monoclonal antibody disclosed herein and an effector molecule. In some aspects, the effector molecule is a toxin, a detectable label, or a photon absorber. In some examples, the toxin is a Pseudomonas exotoxin or a variant thereof, such as PE38. In some examples, the detectable label is a fluorophore, an enzyme or a radioisotope. In some examples, the photon absorber is IR700. Immunoconjugates that include a photon absorber can be used for photoimmunotherapy or in vivo diagnostic imaging. Immunoconjugates are further described in section VII.

[0246] Further provided herein are antibody-nanoparticle conjugates that include a nanoparticle conjugated to a monoclonal antibody disclosed herein. In some aspects, the nanoparticle includes a polymeric nanoparticle, nanosphere, nanocapsule, liposome, dendrimer, polymeric micelle, or niosome. In some examples, the nanoparticular includes a cytotoxic agent. Antibody-nanoparticle conjugates are further described in section VIII.

[0247] Also provided herein are antibody drug conjugates (ADCs) that include a drug conjugated to a monoclonal antibody disclosed herein. In some aspects, the drug is a small molecule, for example an anti-cancer agent, anti-microtubule agent, an anti-mitotic agent, a DNA damaging agent and / or a cytotoxic agent. ADCs are further described in section IX.

[0248] Further provided herein are antibody-proteolysis targeting chimera (PROTAC) conjugates that include a PROTAC conjugated to a monoclonal antibody disclosed herein, hi some aspects, tire PROTAC targets GPR124 or a downstream effector, such as p-catenin, for degradation. In some examples, the antibody-PROTAC conjugate further includes a linker (such as a cleavable linker) between the antibody and tire PROTAC. In some examples, the PROTAC includes a ligand that binds the target protein of interest, a linker and a ligand that binds E3 ubiquitin ligase.

[0249] Also provided herein are isolated nucleic acid molecules that encode a monoclonal antibody, fusion protein, multi-specific antibody, CAR, or immunoconjugate disclosed herein. In some aspects, the nucleic acid molecule is operably linked to a promoter. Further provided are vectors that include such nucleic acid molecules. In some examples, the vector is an expression vector. In other examples, the vector is a viral vector. Isolated cells that include a nucleic acid molecule or vector disclosed herein are further provided. In some examples, the isolated cell is a prokaryotic cell, such as an E. coli cell. In other examples, the isolated cell is a mammalian cell, such as a human cell. Nucleic acid molecules are further described in section X.4239-113261-02

[0250] Compositions that include a pharmaceutically acceptable carrier and a monoclonal antibody, fusion protein, multi-specific antibody, CAR, isolated cell, immunoconjugate, antibody-nanoparticle conjugate, ADC, antibody-PROTAC conjugate, nucleic acid molecule, or tire vector disclosed herein are further provided. Compositions are further described in section XI.

[0251] Also provided are methods of treating a disease or disorder of the central nervous system (CNS) in a subject in need thereof. In some aspects, the method includes administering to the subject an effective amount of a monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate, or composition disclosed herein; and administering to the subject a therapeutic agent for the treatment of the CNS disease or disorder. The effective amount of the monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate, or composition is an amount that increases delivery of the therapeutic agent across the blood-brain-tumor barrier (BBTB) compared to delivery of the therapeutic agent in the absence of the monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate or composition.

[0252] In some aspects of the method, the disease or disorder of the CNS is a brain cancer or brain metastasis. In some examples, the therapeutic agent includes an anti-tumor agent, such as an ADC, CAR-expressing immune cell (such as a CAR T cell), immunotoxin or another antibody conjugate that specifically targets a tumor or tumor-associated antigen. In specific examples in which the antitumor agent is an ADC, the drug of the ADC is an anti-microtubule agent, a DNA damaging agent or an interstrand crosslinking agent, such as a pyrrolobenzodiazepine (PBD).

[0253] In other examples, the anti-tumor agent is a chemotherapeutic agent, such as but not limited to, paclitaxel or a derivative thereof, such as Abraxane, temozolomide, or deruxtecan.

[0254] In some examples, the brain cancer is a glioma, glioblastoma, nemoblastoma, chondrosarcoma, medulloblastoma, meningioma, ependymoma, astrocytoma, oligodendroglioma, pituitary adenoma, pituitary carcinoma, craniopharyngioma, mixed glioma, pinealoma, atypical teratoid rhabdoid tumor, hemangioblastoma, germ cell tumor, Schwannoma, choroid plexus tumor, ganglioglioma, chordoma, anaplastic astrocytoma, primary CNS lymphoma or primitive neuroectodermal tumor. In some examples, tire brain metastasis is a metastasis of a breast cancer, colon cancer, kidney cancer, lung cancer, melanoma, or thyroid cancer.

[0255] In other aspects of the method, tire disease or disorder of tire CNS is epilepsy, multiple sclerosis, Alzheimer's disease, Parkinson’s disease, amyotrophic lateral sclerosis, stroke, meningitis, encephalitis, cerebral palsy, Huntington disease, Bell’s palsy, Lewy body dementia, or cerebrovascular disease.

[0256] Further provided are methods of inhibiting or reducing tumor vasculature in a subject with a tumor. In some aspects, the method includes administering to the subject an effective amount of a monoclonal antibody, fusion protein, multi-specific antibody, CAR, isolated cell, immunoconjugate, antibody-nanoparticle conjugate, ADC, nucleic acid molecule, vector, antibody-PROTAC conjugate, or composition disclosed herein. Such methods are further described in section XII.4239-113261-02

[0257] Also provided are methods of detecting expression of GPR124 in a sample. In some aspects, tlie metiiod includes contacting the sample with a monoclonal antibody, fusion protein or multispecific antibody disclosed herein, and detecting binding of the monoclonal antibody, fusion protein or multi-specific antibody to tire sample, thereby detecting expression of GPR124 in die sample. In some examples, die sample is a biological sample, such as a sample diat includes blood or a blood product, or tissues / cells. In some examples, the medrod detects GPR124-expressing tumor vasculature.

[0258] V. Multi-Specific Antibodies

[0259] Multi-specific antibodies are recombinant proteins comprised of two or more monoclonal antibodies or antigen-binding fragments of two or more different monoclonal antibodies. For example, bispecific antibodies are comprised of two different monoclonal antibodies or antigenbinding fragments thereof. Thus, bispecific antibodies bind two different antigens (or two different epitopes of the same antigen) and trispecific antibodies bind three different antigens (or three different epitopes of the same antigen).

[0260] Provided herein are multi-specific, such as trispecific or bispecific, monoclonal antibodies that include a first GPR 124- targeted monoclonal antibody. In some aspects, the multi-specific monoclonal antibody further includes a second antibody that binds (such as specifically binds) a different epitope of GPR124 or a different cell-surface antigen. In some aspects, the multi-specific antibody further includes a second antibody that specifically binds CD3. In some aspects, the multispecific monoclonal antibody further includes a second antibody that specifically binds PD-1 (such as nivolumab, JTX-4014 by Jounce Therapeutics, nivolumab, pembrolizumab, pidilizumab, cemiplimab, spartalizumab (PDR001), camrelizumab (SHR1210), sintilimab (IBI308), tislelizumab (BGB-A317), toripalimab (JS 001), dostarlimab (TSR-042, WBP-285), INCMGA00012 (MGA012), AMP-224, or AMP-514). In some aspects, the multi-specific monoclonal antibody further includes a second antibody that specifically binds CTLA-4 (such as ipilimumab or tremelimumab).

[0261] In some aspects disclosed herein, tire multi-specific monoclonal antibody includes a first monoclonal antibody targeted to GPR124 (such as a GPR124- targeted scFv) and further includes a monoclonal antibody (or antigen-binding fragment such as an scFv) that specifically binds a component of the T cell receptor, such as CD3. In other aspects, the multi- specific monoclonal antibody includes a first monoclonal antibody targeted to GPR124 (such as an anti-GPR124 scFv) and further includes a monoclonal antibody (or antigen-binding fragment such as an scFv) that specifically binds a NK cell activating receptor, such as CD16, Ly49, or CD94.

[0262] In some aspects, the multi-specific antibody is a bispecific antibody that includes the VH and VL domains of antibody T502 or T519 and the VH and VL domains of a monoclonal antibody that specifically binds CD3.4239-113261-02

[0263] Also provided are isolated nucleic acid molecules and vectors encoding the multi-specific antibodies, and host cells comprising the nucleic acid molecules or vectors. Multi- specific antibodies that include a GPR124-targeted antibody can be used to enhance the delivery of therapeutic agents across die BBTB and / or reduce or inhibit tumor vascularization.

[0264] VI. Chimeric Antigen Receptors (CARs)

[0265] The disclosed anti-GPR124 monoclonal antibodies (including antigen-binding fragments) can be used to produce CARs (also known as chimeric T cell receptors, artificial T cell receptors or chimeric immunoreceptors) and / or immune cells, such as T lymphocytes (such as CTLs), B cells, natural killer (NK) cells, dendritic cells or macrophages, engineered to express CARs. Induced pluripotent stem cells (iPSCs) can also be used to express CARs. Generally, CARs include a binding moiety, an extracellular hinge and spacer element, a transmembrane region and an endodomain that performs signaling functions (Cartellieri et al., J Biomed Biotechnol 2010:956304, 2010; Dai et al., J Natl Cancer Inst 108(7):djv439, 2016). In many instances, the binding moiety is an antigen binding fragment of a monoclonal antibody, such as a scFv, or a single-domain antibody. The spacer / hinge region typically includes sequences from IgG subclasses, such as IgGl, IgG4, IgD, CDS, or CD28. The transmembrane domain can be derived from a variety of different T cell proteins, such as CD3^, CD4, CD8 or CD28. Several different endodomains have been used to generate CARs. For example, the endodomain can consist of a signaling chain having an IT AM, such as CD3^ or FceRIy. In some instances, the endodomain further includes the intracellular portion of at least one additional costimulatory domain, such as CD28, 4-1BB (CD137, TNFRSF9), OX-40 (CD134), ICOS, CD27 and / or DAP10.

[0266] Immune cells, such as T cells, B cells, NK cells, dendritic cells, or macrophages, or iPSCs expressing CARs can be used to target a specific cell type, such as GPR124-positive tumor vasculature. Thus, the antibodies disclosed herein can be used to engineer immune cells or iPSCs that express a CAR containing the GPR124-targeted monoclonal antibody or antigen-binding fragment thereof, thereby targeting the engineered cells to GPR124-positive tumor vasculature.

[0267] Multispecific (such as bispecific) or bicistronic CARs are also contemplated by the present disclosure. In some aspects, the multispecific or bispecific CAR includes a monoclonal antibody (such as an scFv) targeted to GPR124 and a monoclonal antibody specific for a different antigen (or a different epitope of GPR124). Similarly, a bicistronic CAR includes two CAR molecules expressed from the same construct where one CAR molecule is a GPR124-targeted CAR and the second CAR targets a second antigen, such as a second tumor antigen (see, for example, Qin et al., Blood 130:810, 2017; and WO / 2018 / 213337).

[0268] Accordingly, provided herein are CARs that include a GPR124-targeted antibody, such as T502 or T519, or any antibody having the CDR sequences of T502 or T519. Also provided are4239-113261-02

[0269] isolated nucleic acid molecules and vectors encoding the CARs (including bispecific and bicistronic CARs), and host cells, such as T cells, B cells, NK cells, DCs, macrophages or iPSCs expressing tire CARs, bispecific CARs or bicistronic CARs. T cells, B cells, NK cells, DCs, macrophages or iPSCs expressing CARs comprised of a GPR124-targeted monoclonal antibody or antigen-binding fragment can be used, for example, to reduce or inhibit the development of tumor vasculature. In some aspects herein, tire CAR is a monospecific CAR. In other aspects, the CAR is a bispecific CAR. In other aspects herein, the CAR is a bicistronic CAR.

[0270] In some aspects, the CAR includes a signal peptide sequence, for example, N-terminal to the antigen-binding domain. The signal peptide sequence can be any suitable signal peptide sequence, such as a signal sequence from granulocyte-macrophage colony-stimulating factor receptor (GMCSFR), immunoglobulin light chain kappa, or IL-2. While the signal peptide sequence may facilitate expression of the CAR on the surface of the cell, the presence of the signal peptide sequence in an expressed CAR is not necessary for the CAR to function. Upon expression of the CAR on the cell surface, the signal peptide sequence may be cleaved off of the CAR. Accordingly, in some aspects, the CAR lacks a signal peptide sequence.

[0271] In some aspects, the GPR124-targeted CAR includes the following features in an N-terminal to C-terminal direction: signal peptide, an antigen-binding fragment (such as a scFv in a VH domain-linker- VL domain orientation or in a VL domain-linker- VH domain orientation), a hinge region, a transmembrane domain, a co- stimulatory domain, and a signaling domain.

[0272] Also provided herein are GPR124-targeted monoclonal antibodies modified to enable their use with a universal CAR system. Universal CAR systems have been developed to increase CAR flexibility and expand their use to additional antigens. Currently, for each patient who receives CAR immune cell therapy, autologous immune cells (such as T cells) must be cultured, expanded, and modified to express an antigen-specific CAR. This process is lengthy and expensive, limiting its use. Universal CARs are based on a system in which tire signaling components of the CAR are split from tlie antigen-binding portion of the molecule but come together using a “lock-key” system. For example, biotin-binding immune receptor (BBIR) CARs are comprised of an intracellular T cell signaling domain fused to an extracellular domain comprising avidin. Biotinylated antigen-specific (such as GPR124-targeted) monoclonal antibodies can dren bind the BBIR to direct immune cells to antigen-expressing cells. Another example is the split, universal and programmable (SUPRA) CAR system. In tire SUPRA system, the CAR includes the intracellular signaling domains fused to an extracellular leucine zipper, which is paired with an antigen-specific monoclonal antibody fused to a cognate leucine zipper. For a review of universal CAR systems, see, for example, Zhao et al., J Hematol Oncol 11(1): 132, 2018; and Cho et al., Cell 173:1426-1438, 2018. In some aspects herein, the GPR124-targeted monoclonal antibody is fused to one component of a specific binding pair. In some examples, the monoclonal antibody is fused to a leucine zipper or biotin.4239-113261-02

[0273] Another type of universal CAR can be generated using a sortase enzyme. A sortase is a prokaryotic enzyme that modifies surface proteins by recognizing and cleaving a carboxyl-terminal sorting signal. Sortase catalyzes transpeptidation between a sortase recognition motif and a sortase acceptor motif. Thus, antigen-specific CARs can be generated by contacting an antigen-specific antibody fused to a sortase recognition motif with a portion of a CAR molecule that includes the intracellular signaling domain(s), a transmembrane region and an extracellular portion that includes a sortase acceptor motif. In the presence of the sortase enzyme, the two components become covalently attached to form a complete antigen-specific CAR. Accordingly, in some aspects herein, a GPR124-targeted monoclonal antibody is modified to include a sortase recognition motif (see, for example, PCT Publication No. WO 2016 / 014553).

[0274] In some aspects, the GPR124-targeted CAR is expressed in allogeneic immune cells, such as allogeneic T cells, B cells, NK cells, DCs or macrophages from a healthy donor(s). In some examples, the allogeneic immune cells are genetically engineered to express the GPR124-targeted CAR, for example by disrupting expression of the endogenous T cell receptor by insertion of the CAR (see, for example, MacLeod et al., Mol Ther 25(4): 949-961, 2017). Gene editing can be performed using any appropriate gene editing system, such as CRISPR / Cas9, zinc finger nucleases or transcription activator-like effector nucleases (TALEN).

[0275] VII. Immunoconjugates

[0276] The disclosed monoclonal antibodies can be conjugated to a therapeutic agent or effector molecule. Immunoconjugates include, but are not limited to, molecules in which there is a covalent linkage of a therapeutic agent to an antibody. A therapeutic agent is an agent with a particular biological activity directed against a particular target molecule or a cell bearing a target molecule. One of skill will appreciate that therapeutic agents can include various drugs, such as vinblastine, daunomycin and the like, cytotoxins such as native or modified Pseudomonas exotoxin or diphtheria toxin, encapsulating agents (such as liposomes) that contain pharmacological compositions, radioactive agents such as1251,32P,14C,3H and35S, photon absorbers such as IR700, and other labels, target moieties and ligands.

[0277] The choice of a particular therapeutic agent depends on the target molecule or cell, and the desired biological effect. Thus, for example, the therapeutic agent can be a cytotoxin that is used to bring about the death of a particular target cell (such as a GPR124-expressing cell). Conversely, where it is desired to invoke a non-lethal biological response, the therapeutic agent can be conjugated to a non-lethal pharmacological agent or a liposome containing a non-lethal pharmacological agent.

[0278] With the therapeutic agents and antibodies described herein, one of skill can readily construct a variety of clones containing functionally equivalent nucleic acids, such as nucleic acids which differ in sequence, but which encode the same effector moiety or antibody sequence. Thus, the present disclosure provides nucleic acids encoding antibodies and conjugates and fusion proteins thereof.4239-113261-02

[0279] Effector molecules can be linked to an antibody of interest using any number of known means. Both covalent and noncovalent attachment means may be used. The procedure for attaching an effector molecule to an antibody varies according to the chemical structure of the effector.

[0280] Polypeptides typically contain a variety of functional groups, such as carboxylic acid (COOH), free amine (-NHz) or sulfhydryl (-SH) groups, which are available for reaction with a suitable functional group on an antibody to result in the binding of the effector molecule. Alternatively, the antibody is derivatized to expose or attach additional reactive functional groups. The derivatization may involve attachment of any of a number of known linker molecules. The linker can be any molecule used to join the antibody to the effector molecule. The linker is capable of forming covalent bonds to both the antibody and to the effector molecule. Suitable linkers include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. Where the antibody and the effector molecule are polypeptides, the linkers may be joined to the constituent amino acids through their side groups (such as through a disulfide linkage to cysteine) or to the alpha carbon amino and carboxyl groups of the terminal amino acids.

[0281] In some circumstances, it is desirable to free the effector molecule from the antibody when the immunoconjugate has reached its target site. Therefore, in these circumstances, immunoconjugates include linkages that are cleavable in the vicinity of the target site. Cleavage of the linker to release the effector molecule from the antibody may be prompted by enzymatic activity or conditions to which the immunoconjugate is subjected either inside the target cell or in the vicinity of the target site.

[0282] In view of the large number of methods that have been reported for attaching a variety of radiodiagnostic compounds, radiotherapeutic compounds, labels (such as enzymes or fluorescent molecules), drugs, toxins, and other agents to antibodies, a skilled person will be able to determine a suitable method for attaching a given agent to an antibody or other polypeptide.

[0283] The antibodies disclosed herein can be derivatized or linked to another molecule (such as another peptide or protein). In general, the antibodies or portion thereof is derivatized such that the binding to die target antigen is not affected adversely by die derivatization or labeling. For example, die antibody can be functionally linked (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (for example, a bispecific antibody or a diabody), an Fc protein, a detection agent, a photon absorber, a pharmaceutical agent, and / or a protein or peptide that can mediate association of the antibody or antibody portion with another molecule (such as a streptavidin core region or a poly histidine tag).

[0284] One type of derivatized antibody is produced by cross-linking two or more antibodies (of the same type or of different types, such as to create bispecific antibodies). Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer (such as m-maleimidobenzoyl-N-hydroxysucciniinide ester) or homo bifunctional (such as disuccinimidyl suberate). Such linkers are commercially available.4239-113261-02

[0285] The antibody can be conjugated with a detectable marker, for example, a detectable marker capable of detection by ELISA, spectrophotometry, flow cytometry, microscopy or diagnostic imaging techniques (such as computed tomography (CT), computed axial tomography (CAT) scans, magnetic resonance imaging (MRI), nuclear magnetic resonance imaging (NMRI), magnetic resonance tomography (MTR), ultrasound, fiberoptic examination, and laparoscopic examination). Specific, non-limiting examples of detectable markers include fluorophores, chemiluminescent agents, enzymatic linkages, radioactive isotopes and heavy metals or compounds (for example super paramagnetic iron oxide nanocrystals for detection by MRI). For example, useful detectable markers include fluorescent compounds, including fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-l-napthalenesulfonyl chloride, phycoerythrin, lanthanide phosphors and the like. Bioluminescent markers are also of use, such as luciferase, green fluorescent protein (GFP) and yellow fluorescent protein ( YFP). An antibody can also be conjugated with enzymes that are useful for detection, such as horseradish peroxidase, [3-galactosidase, luciferase, alkaline phosphatase, glucose oxidase and the like. When an antibody or antigen binding fragment is conjugated with a detectable enzyme, it can be detected by adding additional reagents that the enzyme uses to produce a reaction product that can be discerned. For example, when the agent horseradish peroxidase is present, the addition of hydrogen peroxide and diaminobenzidine leads to a colored reaction product, which is visually detectable. An antibody or antigen binding fragment may also be conjugated with biotin and detected through indirect measurement of avidin or streptavidin binding. It should be noted that the avidin itself can be conjugated with an enzyme or a fluorescent label.

[0286] An antibody may be labeled with a magnetic agent, such as gadolinium. Antibodies can also be labeled with lanthanides (such as europium and dysprosium), and manganese. Paramagnetic particles, such as superparamagnetic iron oxide, are also of use as labels. An antibody may also be labeled with a predetermined polypeptide epitope recognized by a secondary reporter (such as leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some aspects, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.

[0287] An antibody can also be labeled with a radiolabeled amino acid. The radiolabel may be used for both diagnostic and dierapeutic purposes. For instance, the radiolabel may be used to detect expression of a target antigen by x-ray, emission spectra, or other diagnostic techniques. Examples of labels for polypeptides include, but are not limited to, die following radioisotopes or radionucleotides:3H,14C,1SN,35S,90Y, "Tc,luIn,125I, and131I.

[0288] An antibody disclosed herein can also be conjugated to a photon absorber. In some aspects, the photon absorber is a phthalocyanine dye, such as, but not limited to, IRDye® 700DX (also known as “IR700”). Antibody-photoabsorber conjugates can be used for photoimmunotherapy (for example to kill GPR124-positive cells).4239-113261-02

[0289] An antibody can also be derivatized with a chemical group such as polyethylene glycol (PEG), a methyl or ethyl group, or a carbohydrate group. These groups may be useful to improve the biological characteristics of the antibody, such as to increase serum half-life or to increase tissue binding.

[0290] Toxins can be employed with the monoclonal antibodies described herein to produce immunotoxins. Exemplary toxins include ricin, abrin, diphtheria toxin and subunits thereof, as well as botulinum toxins A through F. These toxins are readily available from commercial sources (for example, Sigma Chemical Company, St. Louis, MO). Contemplated toxins also include variants of the toxins described herein (see, for example, see, U.S. Patent Nos. 5,079,163 and 4,689,401). In one aspect, the toxin is Pseudomonas exotoxin (PE) (U.S. Patent No. 5,602,095). As used herein, "Pseudomonas exotoxin" refers to a full-length native (naturally occurring) PE or a PE that has been modified. Such modifications can include, but are not limited to, elimination of domain la, various amino acid deletions in domains lb, II and III, single amino acid substitutions and the addition of one or more sequences at the carboxyl terminus (for example, see Siegall et al., J. Biol. Chem. 264:14256-14261, 1989).

[0291] PE employed with the monoclonal antibodies described herein can include the native sequence, cytotoxic fragments of the native sequence, and conservatively modified variants of native PE and its cytotoxic fragments. Cytotoxic fragments of PE include those which are cytotoxic with or without subsequent proteolytic or other processing in the target cell. Cytotoxic fragments of PE include PE40, PE38, and PE35. For additional description of PE and variants thereof, see for example, U.S. Patent Nos. 4,892,827; 5,512,658; 5,602,095; 5,608,039; 5,821,238; and 5,854,044; U.S. Patent Application Publication No. 2015 / 0099707; PCT Publication Nos. WO 99 / 51643 and WO 2014 / 052064; Pai et al., Proc. Natl. Acad. Sci. USA 88:3358-3362, 1991; Kondo et al., J. Biol. Chem.

[0292] 263:9470-9475, 1988; andPastan et al., Biochim. Biophys. Acta 1333:C1-C6, 1997.

[0293] Also contemplated herein are protease-resistant PE variants and PE variants with reduced immunogenicity, such as, but not limited to PE-LR, PE-6X, PE-8X, PE-LR / 6X and PE-LR / 8X (see, for example, Weldon et al., Blood 113(16):3792-3800, 2009; Onda et al., Proc Natl Acad Sci USA 105(32): 11311-11316, 2008; and PCT Publication Nos. WO 2007 / 016150, WO 2009 / 032954 and WO 2011 / 032022).

[0294] In some examples, the PE is a variant that is resistant to lysosomal degradation, such as PE-LR (Weldon et al., Blood 113(16): 3792-3800, 2009; PCT Publication No. WO 2009 / 032954). In other examples, the PE is a variant designated PE-LR / 6X (PCT Publication No. WO 2011 / 032022). In other examples, the PE variant is PE with reducing immunogenicity. In yet other examples, the PE is a variant designated PE-LR / 8M (PCT Publication No. WO 2011 / 032022).

[0295] Modification of PE may occur in any previously described variant, including cytotoxic fragments of PE (for example, PE38, PE-LR and PE-LR / 8M). Modified PEs may include any substitution(s), such as for one or more amino acid residues within one or more T-cell epitopes and / or4239-113261-02

[0296] B cell epitopes of PE, or deletion of one or more T-cell and / or B-cell epitopes (see, for example, U.S. Patent Application Publication No. 2015 / 0099707).

[0297] Contemplated forms of PE also include deimmunized forms of PE, for example versions with domain II deleted (for example, PE24). Deimmunized forms of PE are described in, for example, PCT Publication Nos. WO 2005 / 052006, WO 2007 / 016150, WO 2007 / 014743, WO 2007 / 031741, WO 2009 / 32954, WO 2011 / 32022, WO 2012 / 154530, and WO 2012 / 170617.

[0298] The antibodies described herein can also be used to target any number of different diagnostic or therapeutic compounds to cells expressing GPR124 on their surface (e.g., GPR124-positive cells in tumor vasculature). Thus, an antibody of the present disclosure can be attached directly or via a linker to a drag that is to be delivered directly to cells expressing GPR124. This can be done for therapeutic, diagnostic or research purposes. Therapeutic agents include such compounds as nucleic acids, proteins, peptides, amino acids or derivatives, glycoproteins, radioisotopes, photon absorbers, lipids, carbohydrates, and recombinant viruses. Nucleic acid therapeutic and diagnostic moieties include antisense nucleic acids, derivatized oligonucleotides for covalent cross-linking with single or duplex DNA, and triplex forming oligonucleotides.

[0299] Alternatively, the molecule linked to an antibody can be an encapsulation system, such as a nanoparticle, liposome or micelle that contains a therapeutic composition such as a drag, a nucleic acid (for example, an antisense nucleic acid), or another therapeutic moiety that is shielded from direct exposure to the circulatory system. Means of preparing liposomes attached to antibodies are known (see, for example, U.S. Patent No. 4,957,735; Connor et al., Pharm. Ther. 28:341-365, 1985).

[0300] Antibodies described herein can also be covalently or non-covalently linked to a detectable label. Detectable labels suitable for such use include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels include magnetic beads, fluorescent dyes (for example, fluorescein isothiocyanate, Texas red, rhodamine, green fluorescent protein, and the like), radiolabels (for example,3H,1251,35S,14C, or32P), enzymes (such as horseradish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (such as polystyrene, polypropylene, latex, and the like) beads.

[0301] Means of detecting such labels are known. Thus, for example, radiolabels may be detected using photographic film or scintillation counters, fluorescent markers may be detected using a photodetector to detect emitted illumination. Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting the reaction product produced by the action of the enzyme on the substrate, and colorimetric labels are detected by simply visualizing the colored label.

[0302] VIII. Antibody-Nanoparticle Conjugates

[0303] The monoclonal antibodies disclosed herein can be conjugated to a variety of different types of nanoparticles to deliver cytotoxic agents directly to GPR124-expressing cells via binding of the4239-113261-02

[0304] aiitibody to GPR124 expressed on the surface of cells. The use of nanoparticles reduces off-target side effects and can also improve drug bioavailability and reduce the dose of a drug required to achieve a therapeutic effect. Nanoparticle formulations can be tailored to suit the drug that is to be carried or encapsulated within the nanoparticle. For example, hydrophobic molecules can be incorporated inside the core of a nanoparticle, while hydrophilic drugs can be carried within an aqueous core protected by a polymeric or lipid shell. Examples of nanoparticles include, but at not limited to, nanospheres, nanocapsules, liposomes, dendrimers, polymeric micelles, niosomes, and polymeric nanoparticles (Fay and Scott, Immunotherapy 3(3);381-394, 2011).

[0305] Liposomes are common types of nanoparticles used for drug delivery. An antibody conjugated to a liposome is often referred to as an “immunoliposome.” The liposomal component of an immunoliposome is typically a lipid vesicle of one or more concentric phospholipid bilayers. In some cases, the phospholipids are composed of a hydrophilic head group and two hydrophobic chains to enable encapsulation of both hydrophobic and hydrophilic drugs. Conventional liposomes are rapidly removed from the circulation via macrophages of the reticuloendothelial system (RES). To generate long-circulating liposomes, the composition, size and charge of the liposome can be modulated. The surface of the liposome may also be modified, such as with a glycolipid or sialic acid. For example, the inclusion of polyethylene glycol (PEG) significantly increases circulation halflife. Liposomes for use as drug delivery agents, including for preparation of immunoliposomes, have been described (see, for example, Paszko and Senge, CurrMed Chem 19(31)5239-5277, 2012;

[0306] Immordino et al., Int J Nanomedicine 1(3):297-315, 2006; U.S. Patent Application Publication Nos.

[0307] 2011 / 0268655; 2010 / 00329981).

[0308] Niosomes are non-ionic surfactant-based vesicles having a structure similar to liposomes. The membranes of niosomes are composed only of nonionic surfactants, such as polyglyceryl-alkyl ethers or A-palmitoylglucosamine. Niosomes range from small, unilamellar to large, multilamellar particles. These nanoparticles are monodisperse, water-soluble, chemically stable, have low toxicity, are biodegradable and non-immunogenic, and increase bioavailability of encapsulated drugs.

[0309] Dendrimers include a range of branched polymer complexes. These nanoparticles are water-soluble, biocompatible and are sufficiently non-immunogenic for human use. Generally, dendrimers consist of an initiator core, surrounded by a layer of a selected polymer that is grafted to the core, forming a branched macromolecular' complex. Dendrimers are typically produced using polymers such as poly(amidoamine) or poly(L-lysine). Dendrimers have been used for a variety of therapeutic and diagnostic applications, including for the delivery of DNA, RNA, bioimaging contrast agents, chemotherapeutic agents and other drugs.

[0310] Polymeric micelles are composed of aggregates of amphiphilic co-polymers (consisting of both hydrophilic and hydrophobic monomer units) assembled into hydrophobic cores, surrounded by a corona of hydrophilic polymeric chains exposed to the aqueous environment. In many cases, the polymers used to prepare polymeric micelles are heterobifunctional copolymers composed of a4239-113261-02

[0311] hydrophilic block of PEG, poly(vinyl pyrrolidone) and hydrophobic poly(L-lactide) or poly(L-lysine) that forms the particle core. Polymeric micelles can be used to carry drugs that have poor solubility. These nanoparticles have been used to encapsulate a number of drugs, including doxorubicin and camptothecin. Cationic micelles have also been developed to carry DNA or RNA molecules.

[0312] Polymeric nanoparticles include both nanospheres and nanocapsules. Nanospheres consist of a solid matrix of polymer, while nanocapsules contain an aqueous core. The formulation selected typically depends on the solubility of the therapeutic agent to be carried / encapsulated; poorly water-soluble drugs are more readily encapsulated within nanospheres, while water-soluble and labile drugs, such as DNA and proteins, are more readily encapsulated within nanocapsules. The polymers used to produce these nanoparticles include, for example, poly (acrylamide), poly(ester),

[0313] poly (alkylcyanoacrylates), poly(lactic acid) (PLA), polylglycolic acids) (PGA), and poly(D,L-lactic-co-glycolic acid) (PLGA).

[0314] Antibodies can be conjugated to a suitable nanoparticle according to standard known methods. For example, conjugation can be either covalent or non-covalent. In some aspects in which the nanoparticle is a liposome, the antibody is attached to a sterically stabilized, long circulation liposome via a PEG chain. Coupling of antibodies or antibody fragments to a liposome can also involve thioester bonds, for example by reaction of thiols and maleimide groups. Cross-linking agents can be used to create sulfhydryl groups for attachment of antibodies to nanoparticles (Paszko and Senge, CurrMed Chem 19(31)5239-5277, 2012).

[0315] IX. Antibody-Drug Conjugates (ADCs)

[0316] ADCs are compounds comprised of an antigen-specific antibody (such as a monoclonal antibody or antigen-binding fragment of an immunoglobulin provided herein that binds GPR124) and a drug, for example a cytotoxic agent (such as an anti-microtubule agent, a DNA damaging agent or cross-linking agent). Because ADCs are capable of specifically targeting cells expressing a particular antigen, the drug can be much more potent than agents used for standard systemic therapy. For example, the most common cytotoxic drugs currently used with ADCs have an IC50 that is 100- to 1000-fold more potent than conventional chemotherapeutic agents. Common cytotoxic drugs include anti-microtubule agents, such as maytansinoids and auristatins (such as auristatin E and auristatin F). Other cytotoxins for use with ADCs include pynolobenzodiazepines (PBDs), which covalently bind the minor groove of DNA to form interstrand crosslinks. Some PBDs bind a single strand of DNA, resulting in damage to the DNA. In many instances, ADCs comprise a 1:2 to 1:4 ratio of antibody to drug (Bander, Clinical Advances in Hematology & Oncology 10(8; suppl 10):3-7, 2012).

[0317] The antibody and drug can be linked by a cleavable or non-cleavable linker. However, in some instances, a linker is stable in the circulation to prevent systemic release of the cytotoxic drug that could result in significant off-target toxicity. Non-cleavable linkers prevent release of the cytotoxic agent before the ADC is internalized by the target cell. Once in the lysosome, digestion of4239-113261-02

[0318] the antibody by lysosomal proteases results in the release of the cytotoxic agent (Bander, Clinical Advances in Hematology & Oncology 10(8; suppl 10):3-7, 2012).

[0319] One method for site-specific and stable conjugation of a drug to a monoclonal antibody (or antigen-biding fragment fused to Fc) is via glycan engineering. Monoclonal antibodies have one conserved N-linked oligosaccharide chain at the Asn297 residue in the CH2 domain of each heavy chain (Qasba et al., Biotechnol Prog 24:520-526, 2008). Using a mutant pl,4-galactosyltransferase enzyme (Y289L-Gal-Tl; U.S. Patent Application Publication Nos. 2007 / 0258986 and 2006 / 0084162), 2-keto-galactose is transferred to free GlcNAc residues on the antibody heavy chain to provide a chemical handle for conjugation.

[0320] The oligosaccharide chain attached to monoclonal antibodies can be classified into three groups based on the terminal galactose residues - fully galactosylated (two galactose residues; IgG-G2), one galactose residue (IgG-Gl) or completely degalactosylated (IgG-GO). Treatment of a monoclonal antibody with pl,4-galactosidase converts the antibody to the IgG-GO glycoform. The mutant pl,4-galactosyltransferase enzyme is capable of transferring 2-keto-galactose or 2-azido-galactose from their respective UDP derivatives to the GlcNAc residues on the IgG-Gl and IgG-GO glycoforms. The chemical handle on the transferred sugar enables conjugation of a variety of molecules to the monoclonal antibody via the glycan residues (Qasba et al., Biotechnol Prog 24:520-526, 2008).

[0321] Provided herein are ADCs drat include a drug (such as a cytotoxic agent) conjugated to a monoclonal antibody that binds (such as specifically binds) GPR124. In some aspects, the drug is a small molecule. In some examples, the drug is a cross-linking agent, a DNA damaging agent, an antimicrotubule agent and / or anti-mitotic agent, or any cytotoxic agent suitable for mediating killing of tumor cells. Exemplary cytotoxic agents include, but are not limited to, a PBD, an auristatin, a maytansinoid, dolastatin, calicheamicin, nemorubicin and its derivatives, PNU-159682, anthracy cline, vinca alkaloid, taxane, trichothecene, CC1065, camptothecin, elinafide, a combretastain, a dolastatin, a duocarmycin, an enediyne, a geldanamycin, an indolino-benzodiazepine dimer, a puromycin, a tubulysin, a hemiasterlin, a spliceostatin, or a pladienolide, as well as stereoisomers, isosteres, analogs, and derivatives thereof that have cytotoxic activity.

[0322] In some aspects, the ADC includes a pyrrolobenzodiazepine (PBD). The natural product anthramycin (a PBD) was first reported in 1965 (Leimgruber et al., J Am Chem Soc, 87:5793-5795, 1965; Leimgruber et al.,J Am Chem Soc, 87:5791-5793, 1965). Since then, a number of PBDs, both naturally-occurring and synthetic analogues, have been reported (Gerratana, Med Res Rev 32(2):254-293, 2012; and U.S. Patent Nos. 6,884,799; 7,049,311; 7,067,511; 7,265,105; 7,511,032; 7,528,126; and 7,557,099). As one example, PBD dimers recognize and bind to specific DNA sequences, and have been shown to be useful as cytotoxic agents. PBD dimers have been conjugated to antibodies and the resulting ADC shown to have anti-cancer properties (see, for example, US 2010 / 0203007).4239-113261-02

[0323] Exemplary linkage sites on the PBD dimer include the five-membered pyrrolo ring, the tether between the PBD units, and the N10-C11 imine group (see WO 2009 / 016516; US 2009 / 304710; US 2010 / 047257; US 2009 / 036431; US 2011 / 0256157; and WO 2011 / 130598).

[0324] In some aspects, the ADC includes an antibody conjugated to one or more maytansinoid molecules. Maytansinoids are derivatives of maytansine and are mitotic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub Maytenus serrata (U.S. Patent No. 3,896,111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Patent No.

[0325] 4,151,042). Synthetic maytansinoids are disclosed, for example, in U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533.

[0326] In some aspects, the ADC includes an antibody conjugated to a dolastatin or auristatin, or an analog or derivative thereof (see U.S. Patent Nos. 5,635,483; 5,780,588; 5,767,237; and 6,124,431). Auristatins are derivatives of the marine mollusk compound dolastatin- 10. Dolastatins and auristatins have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cellular division (Woyke et al. , Antimicrob Agents and Chemother 45(12):3580-3584, 2001) and have anticancer (U.S. Patent No. 5,663,149) and antifungal activity (Pettit et al., Antimicrob Agents Chemother 42:2961-2965, 1998). Exemplary dolastatins and auristatins include, but are not limited to, dolastatin 10, auristatin E, auristatin F, auristatin EB (AEB), auristatin EFP (AEFP), MMAD (Monomethyl Auristatin D or monomethyl dolastatin 10), MMAF (Monomethyl Auristatin F or N-methylvaline-valine-dolaisoleuine-dolaproine-phenylalanine), MMAE (Monomethyl Auristatin E or N-methylvaline-valine-dolaisoleuine-dolaproine-norephedrine), 5-benzoylvaleric acid-AE ester (AEVB), and other auristatins (see, for example, U.S. Publication No. 2013 / 0129753).

[0327] In some aspects, the ADC includes an antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics, and analogues thereof, can produce doublestranded DNA breaks at sub-picomolar concentrations (Hinman et al., Cancer Res 53:3336-3342, 1993; Lode et al., Cancer Res 58:2925-2928, 1998). Exemplary methods for preparing ADCs with a calicheamicin drug moiety are described in U.S. Patent Nos. 5,712,374; 5,714,586; 5,739,116; and 5,767,285.

[0328] In some aspects, the ADC includes an anthracycline. Anthracyclines are antibiotic compounds that exhibit cytotoxic activity. It is believed that anthracyclines can kill cells by a number of different mechanisms, including intercalation of tire drug molecules into the DNA of the cell thereby inhibiting DNA-dependent nucleic acid synthesis; inducing production of free radicals which then react with cellular macromolecules to cause damage to the cells; and / or interactions of the drug molecules with the cell membrane. Non-limiting exemplary anthracyclines include doxorubicin, epirubicin, idarubicin, daunomycin, daunorubicin, doxorubicin, epirubicin, nemorubicin, valrubicin4239-113261-02

[0329] aiid mitoxantrone, and derivatives thereof. For example, PNU- 159682 is a potent metabolite (or derivative) of nemorubicin (Quintieri etal., Clin Cancer Res 1 l(4):1608-1617, 2005). Nemorubicin is a semisynthetic analog of doxorubicin with a 2-methoxymorpholino group on tire glycoside amino of doxorubicin (Grandi et al., Cancer Treat Rev 17:133, 1990; Ripamonti et al.,Br J Cancer 65:703-707, 1992).

[0330] In some aspects, the ADC can further include a linker. In some examples, the linker is a bifunctional or multifunctional moiety that can be used to link one or more drug moieties to an antibody to form an ADC. In some aspects, ADCs are prepared using a linker having reactive functionalities for covalently attaching to the drug and to the antibody. For example, a cysteine thiol of an antibody can form a bond with a reactive functional group of a linker or a drug-linker intermediate to make an ADC.

[0331] In some examples, a linker has a functionality that can react with a free cysteine present on an antibody to form a covalent bond. Exemplary linkers with such reactive functionalities include maleimide, haloacetamides, a-haloacetyl, activated esters such as succinimide esters, 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates.

[0332] In some examples, a linker has a functionality that can react with an electrophilic group present on an antibody. Examples of such electrophilic groups include, but are not limited to, aldehyde and ketone carbonyl groups. In some cases, a heteroatom of the reactive functionality of the linker can react with an electrophilic group on an antibody and form a covalent bond to an antibody unit. Non-limiting examples include hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate and arylhydrazide.

[0333] In some examples, the linker is a cleavable linker, which facilitates release of the drug. Examples of cleavable linkers include acid-labile linkers (for example, comprising hydrazone), protease-sensitive linkers (for example, peptidase-sensitive), photolabile linkers, and disulfide-containing linkers (Chari et al., Cancer Res 52:127-131, 1992; U.S. Patent No. 5,208,020).

[0334] X. Nucleic Acid Molecules

[0335] Nucleic acid molecules (for example, DNA, cDNA, mRNA, or RNA molecules) encoding the amino acid sequences of the disclosed antibodies, fusion proteins, CARs and other conjugates that bind (such as specifically bind) to GPR124, are provided. Nucleic acid molecules encoding these molecules can readily be produced using the amino acid sequences provided herein (such as the CDR sequences and the variable domain sequences), sequences available (such as framework or constant region sequences), and the genetic code. In some aspects, the nucleic acid molecules can be expressed in a host cell (such as a mammalian cell or a bacterial cell) to produce a disclosed antibody, fusion protein or antibody conjugate (e.g., CAR, immunotoxin, multi-specific antibody).4239-113261-02

[0336] The genetic code can be used to construct a variety of functionally equivalent nucleic acid sequences, such as nucleic acids that differ in their sequence, but which encode the same antibody sequence, or encode a conjugate or fusion protein including the antibody sequence.

[0337] Nucleic acid molecules encoding the antibodies, fusion proteins, bispecific antibodies, CARs and other conjugates that bind (such as specifically bind) to GPR124 can be prepared by any suitable method including, for example, cloning of appropriate sequences or by direct chemical synthesis by standard methods. Chemical synthesis produces a single stranded oligonucleotide. This can be converted into double stranded DNA by hybridization with a complementary sequence or by polymerization with a DNA polymerase using the single strand as a template.

[0338] Exemplary nucleic acids can be prepared by cloning techniques. Examples of appropriate cloning and sequencing techniques can be found, for example, in Green and Sambrook (Molecular Cloning: A Laboratory Manual, 4thed., New York: Cold Spring Harbor Laboratory Press, 2012) and Ausubel et al. (Eds.) (Current Protocols in Molecular Biology , New York: John Wiley and Sons, including supplements).

[0339] Nucleic acids can also be prepared by amplification methods. Amplification methods include the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), and the self-sustained sequence replication system (3SR).

[0340] The nucleic acid molecules can be expressed in a recombinantly engineered cell such as in bacterial, plant, yeast, insect and mammalian cells. The antibodies and conjugates can be expressed as individual proteins including the antibody (linked to an effector molecule or detectable marker as needed) or can be expressed as a fusion protein. Any suitable method of expressing and purifying antibodies and antigen binding fragments may be used; non-limiting examples are provided in Al-Rubeai (Ed.), Antibody Expression and Production, Dordrecht; New York: Springer, 2011).

[0341] One or more DNA sequences encoding the antibodies, CARs, bispecific antibodies, fusion proteins, or other conjugates can be expressed in vitro by DNA transfer into a suitable host cell. The cell may be prokaryotic or eukaryotic. Numerous expression systems available for expression of proteins including E. coli, other bacterial hosts, yeast, and various higher eukaryotic cells, for example mammalian cells, such as the COS, CHO, HeLa and myeloma cell lines, can be used to express the disclosed antibodies and antigen binding fragments. Methods of stable transfer, meaning that the foreign DNA is continuously maintained in the host, may be used.

[0342] The expression of nucleic acids encoding the antibodies, CARs and other conjugates described herein can be achieved by operably linking the DNA or cDNA to a promoter (which is either constitutive or inducible), followed by incorporation into an expression cassette. The promoter can be any promoter of interest, including a cytomegalovirus promoter. Optionally, an enhancer, such as a cytomegalovirus enhancer, is included in the construct. The cassettes can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression cassettes contain specific sequences useful for regulation of die expression of the DNA encoding the protein. For4239-113261-02

[0343] example, the expression cassettes can include appropriate promoters, enhancers, transcription and translation terminators, initiation sequences, a start codon (i.e., ATG) in front of a protein-encoding gene, splicing signals for introns, sequences for the maintenance of the correct reading frame of that gene to permit proper translation of mRNA, and stop codons. The vector can encode a selectable marker, such as a marker encoding drug resistance (for example, ampicillin or tetracycline resistance).

[0344] To obtain high level expression of a cloned gene, it is desirable to construct expression cassettes which contain, for example, a strong promoter to direct transcription, a ribosome binding site for translational initiation (e.g., internal ribosomal binding sequences), and a transcription / translation terminator. For E. coli, this can include a promoter such as the T7, trp, lac, or lambda promoters, a ribosome binding site, and a transcription termination signal. For eukaryotic cells, the control sequences can include a promoter and / or an enhancer derived from, for example, an immunoglobulin gene, HTLV, S V40 or cytomegalovirus, and a polyadenylation sequence, and can further include splice donor and / or acceptor sequences (for example, CMV and / or HTLV splice acceptor and donor sequences). The cassettes can be transferred into the chosen host cell by any suitable method such as transformation or electroporation for E. coli and calcium phosphate treatment, electroporation or lipofection for mammalian cells. Cells transformed by the cassettes can be selected by resistance to antibiotics conferred by genes contained in the cassettes, such as the amp, gpt, neo and hyg genes.

[0345] Modifications can be made to a nucleic acid encoding an antibody described herein without diminishing its biological activity. Some modifications can be made to facilitate the cloning, expression, or incorporation of the antibody into a fusion protein. Such modifications include, for example, termination codons, sequences to create conveniently located restriction sites, and sequences to add a methionine at the amino terminus to provide an initiation site, or additional amino acids (such as poly His) to aid in purification steps.

[0346] Once expressed, the antibodies, CARs, bispecific antibodies, fusion proteins, and other conjugates can be purified according to standard procedures, including ammonium sulfate precipitation, affinity columns, column chromatography, and the like (see, generally, Simpson et al. (Eds.), Basic methods in Protein Purification and Analysis: A Laboratory Manual, New York: Cold Spring Harbor Laboratory Press, 2009). The antibodies, CARs, bispecific antibodies, fusion proteins, and other conjugates need not be 100% pure. Once purified, partially or to homogeneity as desired, if to be used prophy lactically, the antibodies should be substantially free of endotoxin.

[0347] Methods for expression of antibodies, CARs, fusion proteins, and conjugates, and / or refolding to an appropriate active form, from mammalian cells, and bacteria such as E. coli have been described and are applicable to the antibodies disclosed herein. See, e.g., Greenfield (Ed.), Antibodies: A Laboratory Manual, 2nded. New York: Cold Spring Harbor Laboratory Press, 2014, Simpson et al. (Eds.), Basic methods in Protein Purification and Analysis: A Laboratory Manual, New York: Cold Spring Harbor Laboratory Press, 2009, and Ward et al., Nature 341(6242):544-546, 1989.4239-113261-02

[0348] XI. Compositions and Administration

[0349] Compositions are provided that include one or more of the disclosed monoclonal antibodies that bind (for example specifically bind) GPR124 in a carrier. Compositions comprising fusion proteins (such as scFv-Fc fusion proteins), ADCs, CARs (and immune cells expressing CARs), multispecific (such as bispecific or trispecific) antibodies, antibody-nanoparticle conjugates, antibody-PROTAC conjugates, immunoliposomes and immunoconjugates are also provided, as are nucleic acid molecule and vectors encoding the antibodies or antibody conjugates. The compositions can be prepared in unit dosage form for administration to a subject. The amount and timing of administration are at the discretion of the treating clinician to achieve the desired outcome. The antibody, fusion protein, ADC, CAR, CAR-expressing cell, multi-specific antibody, antibody-nanoparticle conjugate, antibody-PROTAC conjugate, immunoliposome or immunoconjugate can be formulated for systemic or local administration.

[0350] The compositions for administration can include a solution of the antibody, fusion protein, ADC, CAR, CAR-expressing cell (such as a T cell, B cell, DC, NK cell, macrophage or iPSC), multispecific (such as bispecific or trispecific) antibody, antibody-nanoparticle conjugate, antibody-PROTAC conjugate, immunoliposome or immunoconjugate in a pharmaceutically acceptable carrier, such as an aqueous carrier. A variety of aqueous carriers can be used, for example, buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of antibody or antibody conjugate in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with tlie particular mode of administration selected and the subject’s needs.

[0351] An exemplary pharmaceutical composition for intravenous administration includes about 0.1 to 10 mg of an antibody (or fusion protein, ADC, CAR, multi-specific antibody, antibody-nanoparticle conjugate, antibody-PROTAC conjugate, or immunoconjugate), per subject per day. Dosages from 0.1 up to about 100 mg per subject per day may be used, particularly if the agent is administered to a secluded site and not into the circulatory or lymph system, such as into a body cavity or into a lumen of an organ. In some aspects, the composition can be a liquid formulation including one or more antibodies / antibody conjugates in a concentration range from about 0.1 mg / ml to about 20 mg / ml, or from about 0.5 mg / ml to about 20 mg / ml, or from about 1 mg / ml to about 20 mg / ml, or from about 0.1 mg / ml to about 10 mg / ml, or from about 0.5 mg / ml to about 10 mg / ml, or from about 1 mg / ml to about 10 mg / ml. Actual methods for preparing administrable compositions will be known or apparent to a skilled person and are described in more detail in such publications as Remington: The Science and Practice of Pharmacy, 23rderf., Academic Press, 2020.4239-113261-02

[0352] Monoclonal antibodies (or antibody conjugates, or nucleic acid molecules encoding such molecules) may be provided in lyophilized form and rehydrated with sterile water before administration, although they are also provided in sterile solutions of known concentration. The antibody solution can be added to an infusion bag containing 0.9% sodium chloride, USP, and in some cases administered at a dosage of from 0.5 to 15 mg / kg of body weight. Considerable experience is available in the administration of antibody drugs, which have been marketed in the U.S. since the approval of RITUXAN™ in 1997. Antibodies, Fc fusion proteins, ADCs, CARs (or CAR-expressing cells), multi-specific (such as bispecific or trispecific) antibodies, antibody-nanoparticle conjugates, antibody-PROTAC conjugates, immunoliposoines or immunoconjugates can be administered by slow infusion, rather than in an intravenous push or bolus. In one example, a higher loading dose is administered, with subsequent, maintenance doses being administered at a lower level. For example, an initial loading dose of 4 mg / kg may be infused over a period of some 90 minutes, followed by weekly maintenance doses for 4-8 weeks of 2 mg / kg infused over a 30-minute period if the previous dose was well tolerated.

[0353] Controlled release parenteral formulations can be made as implants, oily injections, or as particulate systems. For a broad overview of protein delivery systems see, Banga, A.J., Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, Technomic Publishing Company, Inc., Lancaster, PA, (1995). Particulate systems include, for example, microspheres, microparticles, microcapsules, nanocapsules, nanospheres, and nanoparticles. Microcapsules contain the therapeutic protein, such as a cytotoxin or a drug, as a central core. In microspheres the therapeutic is dispersed throughout the particle. Particles, microspheres, and microcapsules smaller than about 1 pm are generally referred to as nanoparticles, nanospheres, and nanocapsules, respectively. Capillaries have a diameter of approximately 5 pm so that only nanoparticles are administered intravenously. Microparticles are typically around 100 pm in diameter and are administered subcutaneously or intramuscularly. See, for example, Kreuter, J., Colloidal Drug Delivery Systems, J. Kreuter, ed., Marcel Dekker, Inc., New York, NY, pp. 219-342 (1994); and Tice & Tabibi, Treatise on Controlled Drug Delivery, A. Kydonieus, ed., Marcel Dekker, Inc. New York, NY, pp. 315-339, (1992).

[0354] Polymers can be used for ion-controlled release of the antibody-based compositions disclosed herein. Various degradable and nondegradable polymeric matrices for use in controlled drug delivery are known (Langer, Accounts Chem. Res. 26:537-542, 1993). For example, the block copolymer, poloxamer 407, exists as a viscous yet mobile liquid at low temperatures but forms a semisolid gel at body temperature. It is an effective vehicle for formulation and sustained delivery of recombinant interleukin-2 and urease (Johnston et al., Pharm. Res. 9:425-434, 1992; and Pec et al., J. Parent. Sci. Tech. 44(2):58-65, 1990). Alternatively, hydroxyapatite has been used as a microcarrier for controlled release of proteins (Ijntema et al., Int. J. PharmA\22 5-224, 1994). hi yet another aspect,4239-113261-02

[0355] liposomes are used for controlled release as well as drug targeting of the lipid-capsulated drug (Betageri et al., Liposome Drug Delivery Systems, Technomic Publishing Co., Inc., Lancaster, PA (1993)). Numerous additional systems for controlled delivery of therapeutic proteins are known (see U.S. Patent Nos. 5,055,303; 5,188,837; 4,235,871; 4,501,728; 4,837,028; 4,957,735; 5,019,369; 5,055,303; 5,514,670; 5,413,797; 5,268,164; 5,004,697; 4,902,505; 5,506,206; 5,271,961; 5,254,342 and 5,534,496).

[0356] XII. Therapeutic Methods

[0357] Provided herein are methods of treating a disease or disorder of the central nervous system (CNS) in a subject in need thereof. In some aspects, the method includes administering to the subject an effective amount of a monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate, or composition disclosed herein; and administering to the subject a therapeutic agent for the treatment of die CNS disease or disorder. The effective amount of the monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate, or composition is an amount that increases delivery of the therapeutic agent across the BBTB compared to delivery of the therapeutic agent in the absence of the monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate or composition. In the context of this method, the “therapeutic agent” refers to a therapeutic agent that is not the GPR124-targeted monoclonal antibody, fusion protein, multi- specific antibody, antibody-PROTAC conjugate, or composition. The therapeutic agent is any agent capable of treating the disease or disorder of the CNS, the delivery of which is increased by administration of the GPR124-targeted monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate, or composition.

[0358] In some aspects of the method, the disease or disorder of the CNS is a brain cancer or brain metastasis. In some examples, the brain cancer is a glioma, glioblastoma, neuroblastoma, chondrosarcoma, medulloblastoma, meningioma, ependymoma, astrocytoma, oligodendroglioma, pituitary adenoma, pituitary carcinoma, craniopharyngioma, mixed glioma, pinealoma, atypical teratoid rhabdoid tumor, hemangioblastoma, germ cell tumor, Schwannoma, choroid plexus tumor, ganglioglioma, chordoma, anaplastic astrocytoma, primary CNS lymphoma or primitive neuroectodermal tumor. In some examples, tire brain metastasis is a metastasis of a breast cancer, colon cancer, kidney cancer, lung cancer, melanoma, or thyroid cancer.

[0359] In some examples, the therapeutic agent includes an anti-tumor agent, such as an ADC, CAR-expressing immune cell (such as a CAR T cell), immunotoxin or another antibody conjugate that specifically targets a tumor or tumor-associated antigen. In specific examples in which the anti-tumor agent is an ADC, the drag of the ADC is an anti-microtubule agent, a DNA damaging agent or an interstrand crosslinking agent, such as a pyrrolobenzodiazepine (PBD).4239-113261-02

[0360] In other examples, the anti-tumor agent is a chemotherapeutic agent, such as but not limited to, paclitaxel or a derivative thereof, temozolomide, or deruxtecan. Other chemotherapeutic agents are known (such as those listed below) and can be selected by a skilled person.

[0361] In aspects in which the disease or disorder of the CNS is a brain tumor or brain metastasis, it is not necessary for the tumor or metastasis to be completely eliminated or inhibited for die method to be effective. For example, the method can decrease tumor size (e.g., volume) or metastasis by a particular amount, for example by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or even 100% as compared to the absence of the treatment. In some examples, the method increases survival time of a subject with a brain cancer or brain metastasis, for example by at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 12 months, at least 18 months, at least 24 months, at least 36 months, at least 48 months, or at least 60 months (such as 2-72 months, 6-12 months, or 3-24 months), for example as compared to a survival time without a disclosed treatment.

[0362] In other aspects of the method, the disease or disorder of the CNS is epilepsy, multiple sclerosis, Alzheimer's disease, Parkinson’s disease, amyotrophic lateral sclerosis, stroke, meningitis, encephalitis, cerebral palsy, Huntington disease, Bell’s palsy, Lewy body dementia, or cerebrovascular disease. Therapeutic agents for the treatment of such diseases are well-known and can be selected by a skilled person. It is not necessary for the disease or disorder to be completely eliminated for the method to be effective. In some examples, signs or symptoms of the disease or disorder can be reduced by a specific amount, for example by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or even 100% as compared to the absence of the treatment. In some examples, the method increases survival time of tire subject with the disease or disorder of the CNS, for example by at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 12 months, at least 18 months, at least 24 months, at least 36 months, at least 48 months, or at least 60 months (such as 2-72 months, 6-12 months, or 3-24 months), for example as compared to a survival time without a disclosed treatment.

[0363] Further provided are methods of inhibiting or reducing tumor vasculature in a subject with a tumor. In some aspects, the method includes administering to die subject an effective amount of a monoclonal antibody, fusion protein, multi-specific antibody, CAR, isolated cell, immunoconjugate, antibody-nanoparticle conjugate, ADC, nucleic acid molecule, vector, antibody-PROTAC conjugate, or composition disclosed herein. In these mediods, the monoclonal antibody, fusion protein, multispecific antibody, CAR, isolated cell, immunoconjugate, antibody-nanoparticle conjugate, ADC, nucleic acid molecule, vector, antibody-PROTAC conjugate, or composition targets GPR124-expressing tumor vasculature for cell killing, thereby reducing or inhibiting the development of tumor vasculature. It is not necessary for the tumor vasculature to be completely eliminated or inhibited for4239-113261-02

[0364] thc method to be effective. For example, the method can reduce tumor vasculature by a particular amount, for example by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or even 100% as compared to the absence of the treatment.

[0365] An effective amount (or a therapeutically effective amount) of a GPR124-targeted monoclonal antibody, ADC, CAR (for example an immune cell or iPSC expressing a CAR), multispecific (such as bispecific or trispecific) antibody, immunoconjugate, antibody-nanoparticle conjugate, antibody-PROTAC conjugate, or composition disclosed herein will depend upon the severity of tire disease, the type of disease, and the general state of the patient's health. A therapeutically effective amount of the antibody-based composition is that which provides either subjective relief of a symptom(s) or an objectively identifiable improvement as noted by the clinician or other qualified observer. Antibodies and conjugates (or CAR-expressing cells) or compositions thereof can be administered, for example, by intravenous infusion. Doses of the antibody or conjugate thereof can vary, but generally range between about 0.5 mg / kg to about 50 mg / kg, such as a dose of about 1 mg / kg, about 5 mg / kg, about 10 mg / kg, about 20 mg / kg, about 30 mg / kg, about 40 mg / kg, or about 50 mg / kg. In some aspects, the dose of the antibody or conjugate can be from about 0.5 mg / kg to about 5 mg / kg, such as a dose of about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg or about 5 mg / kg. The antibody or conjugate is administered according to a dosing schedule determined by a medical practitioner. In some examples, the antibody-based composition is administered weekly, every two weeks, every three weeks, or every four weeks.

[0366] In some aspects, a subject is administered DNA or RNA encoding a disclosed antibody or conjugate thereof to provide in vivo antibody production, for example using tire cellular machinery of the subject. Any suitable method of nucleic acid administration may be used; non-limiting examples are provided in U.S. Patent No. 5,643,578, U.S. Patent No. 5,593,972 and U.S. Patent No. 5,817,637. U.S. Patent No. 5,880,103 describes several methods of delivery of nucleic acids encoding proteins to an organism. One approach to administration of nucleic acids is direct administration with plasmid DNA, such as with a mammalian expression plasmid. The nucleotide sequence encoding the disclosed antibody, or antigen binding fragments thereof, can be placed under tire control of a promoter to increase expression. The methods include liposomal delivery of the nucleic acids. Such methods can be applied to Ore production of an antibody, or antigen binding fragments thereof.

[0367] In several aspects, a subject is administered an effective amount of a viral vector that includes one or more nucleic acid molecules encoding a disclosed antibody or conjugate. The viral vector is designed for expression of the nucleic acid molecules encoding a disclosed antibody or conjugate, and administration of tire effective amount of the viral vector to tire subject leads to expression of an effective amount of the antibody or conjugate in the subject. Non-limiting examples of viral vectors that can be used to express a disclosed antibody or conjugate in a subject include those provided in Johnson et al., Nat. Med., 15(8):901-906, 2009 and Gardner et al., Nature, 519(7541 ):87-91 , 2015.4239-113261-02

[0368] In one aspect, a nucleic acid encoding a disclosed antibody, or conjugate thereof, is introduced directly into tissue. For example, the nucleic acid can be loaded onto gold microspheres by standard methods and introduced into the skin by a device such as Bio-Rad’s HELIOS™ Gene Gun. The nucleic acids can be “naked,” consisting of plasmids under control of a strong promoter. Typically, the DNA is injected into muscle, although it can also be injected directly into other sites. Dosages for injection are usually around 0.5 |ig / kg to about 50 mg / kg, and typically are about 0.005 mg / kg to about 5 mg / kg (see, e.g., U.S. Patent No. 5,589,466).

[0369] Single or multiple administrations of a composition including a disclosed antibody or antibody conjugate, or nucleic acid molecule encoding such molecules, can be administered depending on the dosage and frequency as required and tolerated by the patient. The dosage can be administered once but may be applied periodically until either a desired result is achieved or until side effects warrant discontinuation of therapy. Generally (in aspects in which the CNS disease or disorder is a brain cancer or brain metastasis), the dose is sufficient to inhibit growth or metastasis of a brain cancer or brain metastasis without producing unacceptable toxicity to the patient.

[0370] Data obtained from cell culture assays and animal studies can be used to formulate a range of dosage for use in humans. The dosage normally lies within a range of circulating concentrations that include the ED50, with little or minimal toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.

[0371] The GPR124-targeted antibody, antibody conjugate, nucleic acid molecule encoding such molecules, or a composition including such molecules, can be administered to subjects in various ways, including local and systemic administration, such as, e.g., by injection subcutaneously, intravenously, intra-arterially, intraperitoneally, intramuscularly, intradermally, intratumorally, intraprostatically, or intratliecally. In some aspects, the composition is administered by inhalation, such as by using an inhaler. In one aspect, the antibody, antigen binding fragment, or nucleic acid molecule encoding such molecules, or a composition including such molecules, is administered by a single subcutaneous, intravenous, intra-arterial, intraperitoneal, intramuscular, intradermal, intratumoral or intrathecal injection once a day. The antibody, antigen binding fragment, bispecific antibody, conjugate, or nucleic acid molecule encoding such molecules, or a composition including such molecules, can also be administered by direct injection at or near the site of disease. A further method of administration is by osmotic pump (e.g., an ALZET pump) or mini-pump (e.g., an ALZET mini-osmotic pump), which allows for controlled, continuous and / or slow-release delivery of the antibody, antibody conjugate, or nucleic acid molecule encoding such molecules, or a composition including such molecules, over a pre-determined period. The osmotic pump or mini-pump can be implanted subcutaneously, or near a target site.

[0372] In some aspects in which the disease or disorder of the CNS is a brain cancer or a brain metastasis, or the method is for targeting GPR124-expressing tumor vasculature, the treatment4239-113261-02

[0373] methods further include administration of other anti-cancer agents or therapeutic treatments. Any suitable anti-cancer agent can be administered in combination with the compositions disclosed herein. Exemplary anti-cancer agents include, but are not limited to, chemotherapeutic agents, such as, for example, mitotic inhibitors, alkylating agents, anti- metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, anti-survival agents, biological response modifiers, anti-hormones (e.g. anti-androgens) and anti-angiogenesis agents. Other anticancer treatments include radiation therapy and other antibodies that specifically target cancer cells.

[0374] Non-limiting examples of alkylating agents include nitrogen mustards (such as mechlorethamine, cyclophosphamide, melphalan, uracil mustard or chlorambucil), alkyl sulfonates (such as busulfan), nitrosoureas (such as carmustine, lomustine, semustine, streptozocin, or dacarbazine).

[0375] Non-limiting examples of antimetabolites include folic acid analogs (such as methotrexate), pyrimidine analogs (such as 5-FU or cytarabine), and purine analogs, such as mercaptopurine or thioguanine.

[0376] Non-limiting examples of natural products include vinca alkaloids (such as vinblastine, vincristine, or vindesine), epipodophyllotoxins (such as etoposide or teniposide), antibiotics (such as dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, or mitomycin C), and enzymes (such as L- asparaginase).

[0377] Non-limiting examples of miscellaneous agents include platinum coordination complexes (such as cis-diamine-dichloroplatinum II also known as cisplatin), substituted ureas (such as hydroxyurea), methyl hydrazine derivatives (such as procarbazine), and adrenocrotical suppressants (such as mitotane and aminoglutethimide).

[0378] Non-limiting examples of hormones and antagonists include adrenocorticosteroids (such as prednisone), progestins (such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and magestrol acetate), estrogens (such as diethylstilbestrol and ethinyl estradiol), antiestrogens (such as tamoxifen), and androgens (such as testosterone propionate and fluoxymesterone). Examples of the most commonly used chemotherapy drugs include Adriamycin, Alkeran, Ara-C, BiCNU, Busulfan, CCNU, Carboplatinum, Cisplatinum, Cytoxan, Daunorubicin, DTIC, 5-FU, Fludarabine, Hydrea, Idarubicin, Ifosfamide, Methotrexate, Mithramycin, Mitomycin, Mitoxantrone, Nitrogen Mustard, Taxol (or other taxanes, such as docetaxel), Velban, Vincristine, VP-16, while some more newer drugs include Gemcitabine (Gemzar), Herceptin, Irinotecan (Camptosar, CPT-11), Leustatin, Navelbine, Rituxan STI-571, Taxotere, Topotecan (Hycamtin), Xeloda (Capecitabine), Zevelin and calcitriol.

[0379] Non-limiting examples of immunomodulators that can be used include AS-101 (Wyeth-Ayerst Labs.), bropirimine (Upjohn), gamma interferon (Genentech), GM-CSF (granulocyte macrophage colony stimulating factor; Genetics Institute), IL-2 (Cetus or Hoffman-LaRoche), human4239-113261-02

[0380] iinmune globulin (Cutter Biological), IMREG (from Imreg of New Orleans, La.), SK&F 106528, and TNF (tumor necrosis factor; Genentech).

[0381] Exemplary biologies that can be used in combination with the disclosed methods include one or more monoclonal antibodies (mAbs) used to treat cancer, such as mAbs specific for EGFR (e.g., cetuximab), VEGF (e.g., bevacizumab), PD-1 (e.g., nivolumab, JTX-4014 by Jounce Therapeutics, nivolumab, pembrolizumab, pidilizumab, cemiplimab, spartalizumab (PDR001), camrelizumab (SHR1210), sintilimab (IBI308), tislelizumab (BGB-A317), toripalimab (JS 001, dostarlimab (TSR-042, WBP-285), INCMGA00012 (MGA012), AMP-224, or AMP-514), mesothelin (e.g., atezolizumab, avelumab, durvalumab, cosibelimab, KN035 (envafolimab), BMS-936559, BMS935559, MEDL4736, MPDL-3280A, or MEDL4737), CD25 (e.g., daclizumab or basiliximab), CD20 (e.g., Tositumomab (Bexxar®); Rituximab (Rituxan, Mabthera); Ibritumomab tiuxetan (Zevalin, for example in combination with yttrium-90 or indium-ill therapy); Ofatumumab (Arzerra®), veltuzumab, obinutuzumab, ublituximab, ocaratuzumab), CD22 (e.g., namatumab, inotuzumab ozogamicin, moxetumomab pasudotox) or CTLA4 (e.g., ipilimumab, tremelimumab). In some examples, the additional therapeutic agent administered is an anti-cancer monoclonal antibody, for example one or more of: 3F8, Abagovomab, Adecatumumab, Afutuzumab, Alacizumab , Alemtuzumab, Altumomab pentetate, Anatumomab mafenatox, Apolizumab, Arcitumomab, Bavituximab, Bectumomab, Belimumab, Besilesomab, Bevacizumab, Bivatuzumab mertansine, Blinatumomab, Brentuximab vedotin, Cantuzumab mertansine, Capromab pendetide, Catumaxomab, CC49, Cetuximab, Citatuzumab bogatox, Cixutumumab, Clivatuzumab tetraxetan, Conatumumab, Dacetuzumab, Detumomab, Ecromeximab, Eculizumab, Edrecolomab, Epratuzumab, Ertumaxomab, Etaracizumab, Farletuzumab, Figitumumab, Galiximab, Gemtuzumab ozogamicin, Girentuximab, Glembatumumab vedotin, Ibritumomab tiuxetan, Igovomab, Imciromab, Intetumumab, Inotuzumab ozogamicin, Ipilimumab, Iratumumab, Labetuzumab, Lexatumumab, Lintuzumab, Lorvotuzumab mertansine, Lucatumumab, Lumiliximab, Mapatumumab, Matuzumab, Mepolizumab, Metelimumab, Milatuzumab, Mitumomab, Morolimumab, Nacolomab tafenatox, Naptumomab estafenatox, Necitumumab, Nimotuzumab, Nofetumomab merpentan, Ofatumumab, Olaratumab, Oportuzumab monatox, Oregovomab, Panitumumab, Pemtumomab, Pertuzumab, Pintumomab, Pritumumab, Ramucirumab, Rilotumumab, Rituximab, Robatumumab, Satumomab pendetide, Sibrotuzumab, Sonepcizumab, Tacatuzumab tetraxetan, Taplitumomab paptox, Tenatumomab, TGN1412, Ticilimumab (tremelimumab), Tigatuzumab, TNX-650, Trastuzumab, Tremelimumab, Tucotuzumab celmoleukin, Veltuzumab, Volociximab, Votumumab, Zalutumumab, or combinations thereof. In a specific example, the disclosed methods are used in combination with a therapeutic PD-1 mAb, such as one or more of nivolumab, JTX-4014 by Jounce Therapeutics, nivolumab, pembrolizumab, pidilizumab, cemiplimab, spartalizumab (PDR001), camrelizumab (SHR1210), sintilimab (IBI308), tislelizumab (BGB-A317), toripalimab (JS 001, dostarlimab (TSR-042, WBP-285), INCMGA00012 (MGA012), AMP-224, and AMP-514.4239-113261-02

[0382] In some examples, the methods further include surgical treatment, for example surgical resection of the cancer or a portion of it. In some examples, the methods further include administration of radiotherapy, for example administration of radioactive material or energy (such as external beam therapy) to the tumor site to help eradicate the tumor or shrink it prior to surgical resection.

[0383] EXAMPLES

[0384] The following examples are provided to illustrate particular features of certain aspects of the disclosure, but the scope of the claims should not be limited to those features exemplified.

[0385] Example 1: Identification and characterization of GPR124- targeted antibodies that block Wnt7 / p-catenin signaling

[0386] To identify monoclonal antibodies (mAbs) capable of selectively opening the BBTB, while not impacting the normal BBB, a panel of fully-human anti-GPR124 mAbs were selected in vitro using antibody phage display. The selection strategy involved the panning of human scFv libraries on purified recombinant GPR124-ED protein, derived from the long N-terminal extracellular domain (ED) of GPR124. The N-terminal ED was chosen because mutation analysis revealed this domain is essential for both Wnt7 / p-catenin-signaling and BBB formation (Posokhova et al., Cell Rep 10:123-130, 2015; Eubelen et al., Science 361(6403):eaatll78, 2018). To identify mAbs with cross-species reactivity, antibodies were serial-selected over both human and mouse GPR124-ED proteins, then tested for GPR124 binding by ELISA, immunofluorescence and flow cytometry. Flow cytometry was used to assess binding of two of the identified antibodies (T502 and T519) and a non-specific IgG control to HEK293 SuperTopFlash (STF) cells 48 hours post transient transfection of GPR124 / pcDNA3 or pcDNA3 empty vector (EV). The results showed that T502 and T519 bound GPR124-expressing cells.

[0387] (FIG. 1).

[0388] GPR124 binders were tested for their ability to block Wnt7 / p-catenin signaling in STF reporter cells that contain a P-catenin responsive TCF / LEF driven luciferase reporter, as P-catenin signaling is critical for GPR124 driven barrier formation (Posokhova et al., Cell Rep 10:123-130, 2015; Cho et al., Neuron 95:1221-1225, 2017). HEK293-STF cells were co-transfected with WNT7A, RECK and hGPR124 constructs and then treated for 48 hours with 100 (ig / rnL of non-specific IgG, T502 scFv, T519 scFv, T502 IgG or T519 IgG. The results showed that T502 scFv and T519 scFv both inhibited reporter activity, although T502 was more potent than T519 (FIG. 2A). Similar results were obtained with T502 and T519 in IgG format (FIG. 2B).

[0389] Three antibody formats of T502 (scFv, Fab and full IgG) were tested at various concentrations for function blocking activity in STF reporter cells. FIGS. 3A-3B show luciferase4239-113261-02

[0390] dose-response values of HEK293-STF cells co-transfected with WNT7A, RECK and hGprl24 (FIG.

[0391] 3A) or mGprl24 (FIG. 3B) vectors and treated for 48 hours with 0 to 100 mg / mL of control IgG or T502 antibody in scFv, Fab and full IgG format. All three antibody formats potently blocked Wnt7 / p-catenin signaling in reporter cells.

[0392] Binding of the T502 and T519 antibodies in Fab format to GPR124 ED was evaluated by SPR. The N-terminal extracellular domains of human and mouse GPR124 were purified from mammalian cells. Each protein was coated at 1000 RU on a new CM5 chip in acetate buffer pH 5.0. The T502 and T519 anti-GPR124 antibodies in Fab (monovalent) format were purified and tested at 6.25, 12.5, 25, 50 and 100 nM, using the Single Cycle Program. SPR data were fitted with the monovalent binding model, and the rate constant was calculated accordingly. As shown in FIG. 4, both Fabs recognized human and mouse GPR124. Fab502 (KD~ 0.35 nM) had a higher affinity than Fab519 (KD~ 69-93 nM), primarily due its slow dissociation rate (kd).

[0393] An additional study was conducted to test binding of T502 in IgG format to human and mouse GPR124. Flow cytometry was used to monitor binding of T502 to 293 cells transiently transfected with mouse Gprl24 or human GPR124 expression vectors. Cells transfected with pcDNA empty vector and cells stained with a non-binding IgG were used as negative controls. No binding of control IgG was detected in cells transfected with pcDNA or vectors encoding human or mouse GPR124 (FIG. 5A). However, T502 bound cells expressing both human and mouse GPR124 (FIG.

[0394] 5B).

[0395] As shown in FIG. 6, T502 specifically binds to GPR124 but does not bind GPR125. Flow cytometry was used to monitor binding of T502 to 293 cells transiently transfected with human or mouse GPR125 expression vectors. GPR125 is the closest homologue of GPR124, and unable to potentiate Wnt7 signaling. The results show that T502 binds GPR124, but is unable to bind human or mouse GPR125.

[0396] Example 2: T502 enhances permeability in GPR124-positive cells

[0397] Impedance was evaluated using Electric Cell-substrate Impedance Sensing (ECIS) assays. Gprl24 knockout (KO) brain endothelial cells (BECs) were isolated from Gprl24 KO mice, immortalized, then transfected with a doxycycline (Dox) inducible GPR124 expression vector.

[0398] Untreated cells (GPR124 ) or cells cultured with doxycycline (GPR124+) were untreated or heated with T502 anti-GPR124 antibody. The results show that T502 was only able to block impedance (barrier properties) in cells expressing GPR124 (FIG. 7).

[0399] Example 3: Evaluation of T502 in brain metastatic breast cancer models

[0400] Before testing the ability of T502 to enhance the activity of antibody-drug conjugates (ADCs) designed to target brain metastases, target expression on the brain metastatic breast cancer lines JIMT1-BR3, HCC1954-SBM and SUM190-BR3 was verified. Flow cytometry was used to monitor4239-113261-02

[0401] expression of HER2 and CD276 in the three brain metastatic breast cancer cell lines using the trastuzumab (HER2-specific) and m276-SL (CD276-specific) antibodies. IgG-SL, which is a nonbinding IgG control that has the same Fc domain as trastuzumab and m276-SL, was included as a negative control. As shown in FIG. 8, both HER2 and CD276 are expressed in each of the JIMT1-BR3, HCC1954-SBM and SUM190-BR3 cell lines. Furthermore, as shown in FIGS. 10A-10D, CD276 and HER2 maintain high expression in brain metastases in vivo. Immunofluorescence staining was used to assess CD276 staining (FIGS. 10A-10B) or HER2 staining (FIGS. 10C-10D) in breast cancer brain metastases from HCC19540SBM or JIMT1-BR3 cell lines. Tumor cells were labelled with GFP (green) and co-localization of signal (yellow) indicated that CD276 and HER2 were expressed in tumor cells.

[0402] A study was conducted to test whether T502 impacts drug responses in tumor cell cytotoxicity assays. Alamar blue assays were used to monitor viability of JIMT1-BR3 cells treated with pyrrolobenzodiazepine (PBD)-labelled ADCs or Abraxane alone or in combination with a control IgG or T502. As shown in FIG. 9A, JIMT1-BR3 cells were treated with an IgG-SL-PBD control, trastuzumab-SL-PBD, trastuzumab-SL-PBD + IgG, or trastuzumab-SL-PBD + T502. As shown in FIG. 9B, JIMT1-BR3 cells were treated with an IgG-SL-PBD control, m276-SL-PBD, m276-SL-PBD + IgG, or m276-SL-PBD + T502. As shown in FIG. 9C, JIMT1-BR3 cells were treated with Abraxane alone, Abraxane + IgG, or Abraxane + T502. For each of these studies, control IgG and T502 were used at a concentration of 50 pg / mL. The IC50 values for the treatments are listed in the graphs of FIGS. 9A-9C. These results demonstrate that T502 had no direct impact on cancer cell viability in vitro. Alamar blue assays were also used to monitor viability of HCC1954-SBM and SUM190-BR3 cells treated with PBD-labelled ADCs (m276-SL-PDB and trastuzumab-SL-PBD). As shown in FIGS. 9D-9E, both types of ADCs significantly reduced cell viability. The IC50 values for these treatments are shown in FIG. 9F.

[0403] A further study evaluated whether T502 is capable of detecting GPR124 in tumor vessels of JIMT1-BR3 brain metastases. Immunofluorescence staining widr the T502 antibody was used to assess GPR124 expression in die vasculature of JIMT1-BR3 breast cancer brain metastases. Tumor cells were labelled with GFP (green). As shown in FIG. 11, T502 detected GPR124-expressing tumor vessels in the brain metastases.

[0404] Example 4: The role of GPR124 in the BBTB

[0405] To investigate the impact of GPR124 on the BBTB, Gprl24 was genetically disrupted in Gprl24 conditional mice following treatment with tamoxifen. Afterwards, GL261 tumor cells were injected intracranially. Once brain tumors formed, sulfo-NHS-biotin tracer was then injected intracardially and brains harvested to assess leakage from brain vasculature (FIG. 12).

[0406] Immunofluorescence staining with Texas Red-streptavidin was used to assess the localization of sulfo-NHS-biotin in Gprl24 wildtype (WT) mice or endothelial cell (EC) Gprl24 conditional4239-113261-02

[0407] kiiockout (CKO) mice. As shown in FIG. 13A, the biotin tracer remained mostly inside the CD31 positive vessels in tumors from WT mice, but readily leaked from tumor vessels in Gprl24 EC CKO mice. Quantification of the leaked (non-CD31 overlapping) sulfo- NHS-biotin is provided in FIG. 13B. These results demonstrate that endothelial Gprl24 deficiency increases leakage of tracer molecule in brain tumors.

[0408] Example 5: T502 augments ADC and chemotherapy treatment of brain metastases Animal studies were conducted to evaluate whether T502 could enhance ADC and Abraxane treatment in metastatic brain cancer models. In a first study, mice were inoculated with IIMT1-BR3 cells on D+l, followed by administration of T502 on D+8, D+15, D+22 and D+29. Trastuzumabbased ADC (trastuzumab-SL-PDB) was administered 20 hours after each dose of T502 to allow time for T502 to open the BBTB (FIG. 14A). Survival was monitored for approximately 6 months.

[0409] Bioluminescence imaging (BLI) was used to monitor growth of luciferase tagged JIMT1-BR3 cells following intracardiac injection (FIG. 14B). Kaplan-Meier analysis was used to monitor survival (FIG. 14C). The results demonstrate that T502 augments trastuzumab-SL-PBD activity against JIMT1-BR3 breast cancer metastasis and extends overall survival in this animal model.

[0410] The JIMT1-BR3 brain metastatic model was also used to evaluate the effect of T502 on treatment with Abraxane, a chemotherapeutic drug. Mice were inoculated with tumor cells (1.75xl05) on Day 0, followed by administration of T502 (10 mg / kg i.p.) on Days 8, 15, 22, and 29, and administration of Abraxane (15 mg / kg i.p.) on Days 9, 16, 23 and 30 (FIG. 15A). BLI imaging was used to monitor tumors in mice from Days 7 to 28. One representative mouse per group is shown in FIG. 15B. Kaplan-Meier analysis was used to monitor survival (FIG. 15C). The results show that T502 improves the activity of Abraxane against JIMT1-BR3 brain metastatic breast cancer and extends survival time in treated mice.

[0411] The effect of T502 on treatment with HER2-targeted (trastuzumab-SL-PBD) and CD276-targeted (m276-SL-PDB) ADCs was tested in a HCC1954-SBM brain metastatic breast cancer model. Mice were administered vehicle, vehicle + ADC, or T502 + ADC. Kaplan-Meier analyses were used to monitor survival. As shown in FIG. 16A, the addition of T502 to trastuzumab-SL-PBD improved survival compared to mice administered vehicle + trastuzumab-SL-PBD (p - 0.0338). Similarly, T502 improved survival of mice treated with m276-SL-PBD compared to mice treated with vehicle + m276-SL-PBD (p = 0.0101) (FIG. 16B).4239-113261-02

[0412] Example 6: Markers of the BBTB are reduced in brain metastases following endothelial cell deletion of GPR124

[0413] This example describes studies to evaluate the role of GPR124 on markers of the BBTB, including glucose transporter 1 (GLUT1), major facilitator superfamily domain-containing protein 2 (MFSD2A) and Claudin 5.

[0414] Studies were conducted using mice with a conditional endothelial cell deletion of Gprl24 (EC KO) or mice heterozygous for tire Gprl24 endothelial cell deletion (EC het). Mice were inoculated intracranially with E0771-BR5 breast cancer cells and immunofluorescence (IF) analysis of barrier markers (GLUT1, MFSD2A and Claudin 5) in brain metastasis was performed (FIG. 17A). GLUT1 regulates glucose transport; MFSD2A regulates transcytosis; and Claudin 5 regulates tight junction formation. The levels of these proteins serve as markers of barrier properties.

[0415] As shown in FIG. 17B, lower GLUT1 levels were observed in the CD31 positive vessels of tumors from conditional Gprl24 knockout (EC KO) versus Gprl24 heterozygous (EC het) mice. As shown in FIG. 17C, lower MFSD2A levels were found in the CD31 positive vessels of tumors from conditional Gprl24 knockout (EC KO) versus Gprl24 heterozygous (EC het) mice. Similarly, lower claudin-5 levels were observed in tumors of Gprl24 knockout (EC KO) mice versus Gprl24 heterozygous (EC het) mice (FIGS. 18A-18C).

[0416] Example 7: Increased perfusion of Sulfo-NHS-Biotin tracer in E0771-BR5 brain metastases following endothelial cell deletion of GPR124

[0417] The study design for this example is shown in FIG. 19A. Gprl24 EC KO and EC het mice inoculated with E0771-BR5 breast cancer cells were i.c. administered Sulfo-NHS-biotin to evaluate perfusion when GPR124 is deleted. As shown in FIGS. 19B-19D, Gprl24 EC KO mice exhibited significantly increased perfusion in brain metastases compared to Gprl24 EC het mice and normal mice.

[0418] Example 8: Treatment of mice bearing JIMT1-BR3 brain metastases with T502 reduces BBTB marker MFSD2A

[0419] The study design for this example is shown in FIG. 20A. Mice were i.c. inoculated with JIMT1-BR3 cells and after three weeks, i.p. administered T502. IF analysis was performed to evaluate barrier markers in brain metastases. Immunofluorescence staining revealed significantly lower MFSD2A levels in the CD31 positive vessels of tumors following treatment with T502 versus vehicle (FIGS. 20B-20C).4239-113261-02

[0420] Example 9: Increased antibody- fluorophore conjugate (AFC) binding to tumor cells following T502 administration

[0421] The study design for this example is shown in FIG. 21 A. Mice were i.c. inoculated with JIMT1-BR3-Luc / GFP+ cells and after three weeks, i.p. administered T502. Sixteen hours following administration of T502, mice were i.v. administered B7H3-targeted AFC and ex vivo imagining was performed six hours later. Immunofluorescence staining revealed significantly increased levels of B7H3-targeted ADC on GFP positive tumor cells following pretreatment with T502 antibody versus vehicle (FIGS. 21B-21C).

[0422] Example 10: T502 improves survival following m276-SL-PBD ADC treatment of mice with JIMT1-BR3 brain metastases

[0423] The animal study plan for treatment with the combination of anti-GPR124 (T502) and m276-SL-PBD is shown in FIG. 22A. Mice were i.c. inoculated with Luc+ JIMT1-BR3 cells on Day 0, i.p. administered T502 (10 mg / kg) on Days 15, 22 and 20, and i.p. administered ADC (m276-SL-PBD; 0.2 mg / kg) on Days 16, 23 and 30. Kaplan-Meier analysis was used to monitor survival of mice. As shown in FIG. 22B, administration of T502 extended survival time of mice administered m276-SL-PBD compared to mice administered m276-SL-PBD and vehicle.

[0424] It will be apparent that the precise details of the methods or compositions described may be varied or modified without departing from the spirit of the described aspects of the disclosure. We claim all such modifications and variations that fall within the scope and spirit of the claims below.

Claims

4239-113261-02CLAIMS1. A monoclonal antibody that binds G protein-coupled receptor 124 (GPR124), comprising a variable heavy (VH) domain comprising a heavy chain complementarity determining region 1 (HDR1), a HCDR2 and a HCDR3, and a variable light (VL) domain comprising a light chain complementarity determining region 1 (LDR1), a LCDR2 and a LCDR3, wherein:the VH domain comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 1 and the VL domain comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 2; orthe VH domain comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 3 and the VL domain comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 4.

2. The monoclonal antibody of claim 1 , wherein:the amino acid sequences of the HCDR1 , the HCDR2 and the HCDR3 respectively comprise SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7, and the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 respectively comprise SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15;the amino acid sequences of the HCDR1 , the HCDR2 and the HCDR3 respectively comprise SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, and the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 respectively comprise SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 15;the amino acid sequences of the HCDR1 , the HCDR2 and the HCDR3 respectively comprise SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 10, and the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 respectively comprise SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 15;the amino acid sequences of the HCDR1 , the HCDR2 and the HCDR3 respectively comprise SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, and the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 respectively comprise SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15;the amino acid sequences of the HCDR1 , the HCDR2 and the HCDR3 respectively comprise SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23, and the amino acid sequences of the LCDR1, the LCDR2 and tire LCDR3 respectively comprise SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 15; orthe amino acid sequences of the HCDR1 , the HCDR2 and die HCDR3 respectively comprise SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26, and die amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 respectively comprise SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 15.

3. The monoclonal antibody of claim 1 or claim 2, wherein:the amino acid sequence of the VH domain is at least 90% identical to SEQ ID NO: 1 and comprises the HCDR1, HCDR1 and HCDR3 sequences of SEQ ID NO: 1, and the amino acid4239-113261-02sequence of the VL domain is at least 90% identical to SEQ ID NO: 2 and comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 2; orthe amino acid sequence of the VH domain is at least 90% identical to SEQ ID NO: 3 and comprises the HCDR1, HCDR1 and HCDR3 sequences of SEQ ID NO: 3, and the amino acid sequence of the VL domain is at least 90% identical to SEQ ID NO: 4 and comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 4.

4. The monoclonal antibody of any one of claims 1-3, wherein:the amino acid sequence of the VH domain comprises or consists of SEQ ID NO: 1 and the amino acid sequence of the VL domain comprises or consists of SEQ ID NO: 2; orthe amino acid sequence of the VH domain comprises or consists of SEQ ID NO: 3 and the amino acid sequence of the VL domain comprises or consists of SEQ ID NO: 4.

5. The monoclonal antibody of any one of claims 1-4, which is a human monoclonal antibody.

6. The monoclonal antibody of any one of claims 1 -5, wherein the monoclonal antibody is a single chain variable fragment (scFv) or a fragment antigen-binding (Fab).

7. The monoclonal antibody of any one of claims 1-5, wherein the antibody is an IgG.

8. The monoclonal antibody of claim 7, wherein the IgG is an IgGl, IgG2, IgG3 or IgG4.

9. The monoclonal antibody of any one of claims 1-8, wherein the monoclonal antibody enhances delivery of a therapeutic agent across the blood-brain-tumor barrier (BBTB).

10. A fusion protein, comprising the monoclonal antibody of any one of claims 1-9 and a heterologous protein.

11. A fusion protein, comprising the monoclonal antibody of claim 6, wherein the scFv or Fab is fused to an Fc region.

12. A multi-specific antibody comprising the monoclonal antibody of any one of claims 1-9 and at least one additional monoclonal antibody.

13. The multi-specific antibody of claim 12, which is a bispecific antibody.4239-113261-0214. A chimeric antigen receptor (CAR), comprising the monoclonal antibody of any one of claims 1-9.

15. The CAR of claim 14, further comprising a hinge region, a transmembrane domain, an intracellular co-stimulatory signaling domain, an intracellular signaling domain, or any combination thereof.

16. An isolated cell expressing the CAR of claim 14 or claim 15.

17. The isolated cell of claim 16, wherein the cell is an immune cell or an induced pluripotent stem cell (iPSC).

18. An immunoconjugate comprising the monoclonal antibody of any one of claims 1-9 and an effector molecule.

19. The immunoconjugate of claim 18, wherein the effector molecule is a toxin, a detectable label, or a photon absorber.

20. An antibody-nanoparticle conjugate, comprising a nanoparticle conjugated to the monoclonal antibody of any one of claims 1-9.

21. The antibody-nanoparticle conjugate of claim 20, wherein the nanoparticle comprises a polymeric nanoparticle, nanosphere, nanocapsule, liposome, dendrimer, polymeric micelle, or niosome.

22. An antibody drug conjugate (ADC), comprising a drug conjugated to the monoclonal antibody of any one of claims 1-9.

23. The ADC of claim 22, wherein the drug is an anti-microtubule agent, a DNA damaging agent or an interstrand crosslinking agent.

24. An antibody-proteolysis targeting chimera (PROTAC) conjugate, comprising a PROTAC conjugated to the monoclonal antibody of any one of claims 1-9.

25. The antibody-PROTAC conjugate of claim 24, wherein the PROTAC targets GPR124 or p-catenin for degradation.4239-113261-0226. An isolated nucleic acid molecule encoding the monoclonal antibody of any one of claims 1-9, the fusion protein of claim 10 or claim 11 , the multi-specific antibody of claim 12 or claim 13, the CAR of claim 14 or claim 15, or the immunoconjugate of claim 18 or claim 19.

27. The isolated nucleic acid molecule of claim 26, operably linked to a promoter.

28. A vector comprising the nucleic acid molecule of claim 26 or claim 27.

29. A composition comprising a pharmaceutically acceptable carrier and the monoclonal antibody of any one of claims 1-9, the fusion protein of claim 10 or claim 11, the multi-specific antibody of claim 12 or claim 13, the CAR of claim 14 or claim 15, the isolated cell of claim 16 or claim 17, the immunoconjugate of claim 18 or claim 19, the antibody-nanoparticle conjugate of claim 20 or claim 21, the ADC of claim 22 or claim 23, the antibody-PROTAC conjugate of claim 24 or claim 25, the nucleic acid molecule of claim 26 or claim 27, or the vector of claim 28.

30. A method of treating a disease or disorder of the central nervous system (CNS) in a subject in need thereof, comprising:administering to the subject an effective amount of die monoclonal antibody of any one of claims 1-11, the fusion protein of claim 12 or claim 13, the multi-specific antibody of claim 14 or claim 15, the antibody-PROTAC conjugate of claim 24 or claim 25, or a composition thereof; and administering to the subject a therapeutic agent for die treatment of the CNS disease or disorder,wherein the effective amount of the monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate, or composition is an amount tiiat increases delivery of the tiierapeutic agent across the blood-brain-tumor barrier (BBTB) compared to delivery of the tiierapeutic agent in the absence of the monoclonal antibody, fusion protein, multi-specific antibody, antibody-PROTAC conjugate or composition.

31. The method of claim 30, wherein the disease or disorder of the CNS is a brain cancer or brain metastasis.

32. The method of claim 31 , wherein the therapeutic agent comprises an anti-tumor agent.4239-113261-0233. The method of claim 32, wherein the anti-tumor agent comprises an antibody-drug conjugate (ADC) comprising a drug conjugated to an antibody that specifically binds a tumor or a tumor-associated antigen.

34. The method of claim 33, wherein the drug comprises an anti-microtubule agent, a DNA damaging agent or an interstrand crosslinking agent.

35. The method of claim 34, wherein the DNA damaging agent or interstrand crosslinking agent is a pyrrolobenzodiazepine (PBD).

36. The method of claim 32, wherein the anti-tumor agent comprises a chemotherapeutic agent.

37. The method of claim 36, wherein the chemotherapeutic agent is paclitaxel or a derivative thereof, temozolomide, or deruxtecan.

38. A method of inhibiting or reducing tumor vasculature in a subject with a tumor, comprising administering to the subject an effective amount of the monoclonal antibody of any one of claims 1-9, the fusion protein of claim 10 or claim 11, the multi-specific antibody of claim 12 or claim 13, the CAR of claim 14 or claim 15, the isolated cell of claim 16 or claim 17, the immunoconjugate of claim 18 or claim 19, the antibody-nanoparticle conjugate of claim 20 or claim 21, the ADC of claim 22 or claim 23, the nucleic acid molecule of claim 26 or claim 27, the vector of claim 28, the antibody-PROTAC conjugate of claim 24 or claim 25, or the composition of claim 29.